<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">97327</article-id><article-id pub-id-type="doi">10.7554/eLife.97327</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.97327.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>RGS10 deficiency facilitates distant metastasis by inducing epithelial–mesenchymal transition in breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jiang</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Qiu</surname><given-names>Peng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ma</surname><given-names>Tie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bai</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bu</surname><given-names>Jiawen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yueting</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gu</surname><given-names>Xi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4172-9821</contrib-id><email>jadegx@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Department of Oncology, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Department of Anesthesiology, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Department of Pathology, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Department of Nursing, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Breast Surgery of Panjin Central Hospital</institution><addr-line><named-content content-type="city">Panjin</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033vjfk17</institution-id><institution>Wuhan University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>15</day><month>08</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP97327</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-03-04"><day>04</day><month>03</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-06"><day>06</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.04.583283"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-19"><day>19</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97327.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-05-24"><day>24</day><month>05</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97327.2"/></event></pub-history><permissions><copyright-statement>© 2024, Liu, Jiang, Qiu et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Liu, Jiang, Qiu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-97327-v1.pdf"/><abstract><p>Distant metastasis is the major cause of death in patients with breast cancer. Epithelial–mesenchymal transition (EMT) contributes to breast cancer metastasis. Regulator of G protein-signaling (RGS) proteins modulates metastasis in various cancers. This study identified a novel role for RGS10 in EMT and metastasis in breast cancer. RGS10 protein levels were significantly lower in breast cancer tissues compared to normal breast tissues, and deficiency in RGS10 protein predicted a worse prognosis in patients with breast cancer. RGS10 protein levels were lower in the highly aggressive cell line MDA-MB-231 than in the poorly aggressive, less invasive cell lines MCF7 and SKBR3. Silencing <italic>RGS10</italic> in SKBR3 cells enhanced EMT and caused SKBR3 cell migration and invasion. The ability of RGS10 to suppress EMT and metastasis in breast cancer was dependent on lipocalin-2 and <italic>MIR539-5p</italic>. These findings identify RGS10 as a tumor suppressor, prognostic biomarker, and potential therapeutic target for breast cancer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>miRNA</kwd><kwd>metastasis</kwd><kwd>RGS10</kwd><kwd>EMT</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82103468</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Basic research project for universities of Liaoning provincal department of education</institution></institution-wrap></funding-source><award-id>LJKMZ20221155</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100015226</institution-id><institution>345 Talent Project of Shengjing Hospital of China Medical University</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100015226</institution-id><institution>Clinical trial Tree planting project of Shengjing Hospital of China Medical University</institution></institution-wrap></funding-source><award-id>M1953</award-id><principal-award-recipient><name><surname>Gu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The novel action of RGS10 in epithelial–mesenchymal transition in breast cancer is dependent on LNC2 and miR-539-5p, which is identified as a prognostic biomarker for early distant metastasis in breast cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer is the most common cancer among women worldwide. Globally, in 2020, an estimated 2.3 million new cases of breast cancer were diagnosed, and there were approximately 685,000 deaths from the disease (<xref ref-type="bibr" rid="bib40">Sung et al., 2021</xref>). The majority of breast cancer mortality is due to distant metastasis, with 5-year survival estimated at 30% (<xref ref-type="bibr" rid="bib5">American Cancer Society, 2023</xref>). There is a critical need to identify early breast cancer metastasis using prognostic biomarkers to ensure patients receive effective anticancer therapies in a timely manner (<xref ref-type="bibr" rid="bib31">Miglietta et al., 2022</xref>).</p><p>Epithelial–mesenchymal transition (EMT) plays a critical role in tumor progression and metastatic invasion in breast cancer. EMT describes the process by which epithelial cells lose their epithelial characteristics and cell–cell contact and increase their invasive potential (<xref ref-type="bibr" rid="bib37">Singh and Chakrabarti, 2019</xref>). EMT is characterized by a loss of epithelial cell markers, such as cytokeratins and E-cadherin, followed by an upregulation in the expression of mesenchymal cell markers, such as N-cadherin and vimentin. EMT is regulated at different levels by factors involved in cell signaling, transcriptional control, and epigenetic and post-translational modifications (<xref ref-type="bibr" rid="bib23">Lai et al., 2020</xref>).</p><p>Biomarkers of EMT may predict early breast cancer metastasis and facilitate clinical decision-making (<xref ref-type="bibr" rid="bib29">Liu et al., 2016</xref>). The regulator of G protein signaling 10 (RGS10) belongs to the superfamily of RGS proteins that bind and deactivate heterotrimeric G proteins (<xref ref-type="bibr" rid="bib2">Almutairi et al., 2020</xref>). RGS proteins are important mediators of essential cellular processes and may be tumor initiators or tumor suppressors (<xref ref-type="bibr" rid="bib27">Li et al., 2023</xref>). The canonical function of RGS proteins is to act as GTPase-activating proteins (GAPs), accelerate GTP hydrolysis on G-protein alpha subunits, and terminate signaling pathways downstream of G protein-coupled receptors (<xref ref-type="bibr" rid="bib22">Hunt et al., 1996</xref>). RGS proteins can have noncanonical GAP-independent functions, including the suppression of transforming growth factor beta (TGF-β)-induced EMT in non-small cell lung cancer by RGS6 (<xref ref-type="bibr" rid="bib42">Wang et al., 2022</xref>).</p><p>RGS10 is a critical regulator of cell survival, polarization, adhesion, chemotaxis, and differentiation that exhibits tumor-suppressing effects in ovarian and colorectal cancer. In ovarian cancer cells, <italic>RGS10</italic> suppression increases proliferation by phosphorylation of mTOR, 4E-BP1, p70S6K, and rProtein-S6, including in the presence of chemotherapy (<xref ref-type="bibr" rid="bib4">Altman et al., 2015</xref>), loss of <italic>RGS10</italic> expression contributes to the development of chemoresistance (<xref ref-type="bibr" rid="bib7">Cacan et al., 2014</xref>), and modulating RGS10 expression can alter sensitivity to paclitaxel, cisplatin, and vincristine (<xref ref-type="bibr" rid="bib7">Cacan et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Hooks et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Hooks and Murph, 2015</xref>). In ovarian tumors, transcription of RGS10 is regulated by DNA methylation and histone deacetylation (<xref ref-type="bibr" rid="bib34">Nguyen et al., 2014</xref>). In colorectal cancer, RGS10 expression is suppressed, and inhibition of DNA methylation may contribute to improved prognosis (<xref ref-type="bibr" rid="bib9">Caldiran and Cacan, 2022</xref>).</p><p>In breast cancer, RGS10 is downregulated in heavily metastatic human breast cancer cell populations compared to weakly metastatic human breast cancer cell populations (<xref ref-type="bibr" rid="bib32">Montel et al., 2005</xref>; <xref ref-type="bibr" rid="bib38">Steeg, 2005</xref>). The mechanisms underlying the metastasis-suppressing function of RGS10 in breast cancer remain to be elucidated. In this study, we investigated the function of RGS10 in breast cancer, specifically in breast cancer metastasis. The objectives were to (1) characterize the expression of RGS10 in freshly resected breast cancer and adjacent normal breast tissues; (2) determine the prognostic significance of RGS10 expression in patients with breast cancer; and (3) explore the role of RGS10 and upstream effectors in tumor progression and metastasis in breast cancer cells in vitro and in vivo.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Expression and prognostic associations of <italic>RGS10</italic> in breast cancer</title><p>To determine the role of RGS10 in breast cancer, we analyzed <italic>RGS10</italic> mRNA levels in normal tissues (n = 31) from the Genotype-Tissue Expression dataset, which showed <italic>RGS10</italic> mRNA levels were high in normal breast, blood, colon, and small intestine tissues and low in normal heart, liver, and pancreas tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Next, we determined <italic>RGS10</italic> mRNA levels in cell lines representing 21 human cancers from the Cancer Cell Line Encyclopedia database (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Finally, we applied RT-qPCR in freshly resected breast cancer tissues (n = 20) and matched adjacent normal breast tissues, and showed <italic>RGS10</italic> mRNA levels were lower in breast cancer tissues compared to normal breast tissues (p=0.003; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). The clinicopathological characteristics of these 20 patients are shown in <xref ref-type="table" rid="table1">Table 1</xref>. This pattern implied a downregulation of RGS10 expression in breast cancer tissues.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The expression and prognostic associations of RGS10 in breast cancer.</title><p>(<bold>A</bold>) <italic>RGS10</italic> mRNA levels in 31 normal human tissues. Data were derived from the Genotype-Tissue Expression database. (<bold>B</bold>) <italic>RGS10</italic> mRNA levels in cell lines representing 21 human cancers. Data were derived from the Cancer Cell Line Encyclopedia database. (<bold>C</bold>) qRT-PCR showing <italic>RGS10</italic> mRNA levels in freshly resected breast cancer tissues (n = 20) and matched adjacent normal breast tissues. **p&lt;0.01, Student’s <italic>t</italic> -test. (<bold>D, E</bold>) Survival analyses showing disease-free survival (DFS) (<bold>D</bold>) and overall survival (OS) (<bold>E</bold>) in patients with breast cancer stratified by high versus low <italic>RGS10</italic> mRNA levels. Data were derived from the Kaplan–Meier plotter database. (<bold>F</bold>) Representative images showing immunohistochemical staining of RGS10 protein expression in breast cancer tissues or normal tissues (n = 133) (magnification: ×200 and ×400). (<bold>G, H</bold>) Kaplan–Meier analysis showing DFS (<bold>G</bold>) and OS (<bold>H</bold>) in patients with breast cancer stratified by presence versus absence of RGS10 protein in breast cancer tissues (n = 133).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original files for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig1-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinicopathological characteristics of 20 patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Clinicopathological characteristics</th><th align="left" valign="bottom">Patient 1</th><th align="left" valign="bottom">Patient 2</th><th align="left" valign="bottom">Patient 3</th><th align="left" valign="bottom">Patient 4</th><th align="left" valign="bottom">Patient 5</th></tr></thead><tbody><tr><td align="left" valign="bottom">Sex</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td></tr><tr><td align="left" valign="bottom">Age (years)</td><td align="char" char="." valign="bottom">58</td><td align="char" char="." valign="bottom">40</td><td align="char" char="." valign="bottom">70</td><td align="char" char="." valign="bottom">38</td><td align="char" char="." valign="bottom">58</td></tr><tr><td align="left" valign="bottom">T grade</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">N grade</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Menopausal status</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Postmenopausal</td></tr><tr><td align="left" valign="bottom">Subclass</td><td align="left" valign="bottom">Luminal A</td><td align="left" valign="bottom">Luminal A</td><td align="left" valign="bottom">Luminal A</td><td align="left" valign="bottom">Luminal A</td><td align="left" valign="bottom">Luminal A</td></tr><tr><td align="left" valign="bottom">Metastasis</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Patient 6</bold></td><td align="left" valign="bottom">Patient 7</td><td align="left" valign="bottom"><bold>Patient 8</bold></td><td align="left" valign="bottom"><bold>Patient 9</bold></td><td align="left" valign="bottom"><bold>Patient 10</bold></td></tr><tr><td align="left" valign="bottom">Sex</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td></tr><tr><td align="left" valign="bottom">Age (years)</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">56</td><td align="char" char="." valign="bottom">80</td><td align="char" char="." valign="bottom">55</td><td align="char" char="." valign="bottom">37</td></tr><tr><td align="left" valign="bottom">T grade</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">N grade</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom">Menopausal status</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Premenopausal</td></tr><tr><td align="left" valign="bottom">Subclass</td><td align="left" valign="bottom">Luminal B</td><td align="left" valign="bottom">Luminal B</td><td align="left" valign="bottom">Luminal B</td><td align="left" valign="bottom">Luminal B</td><td align="left" valign="bottom">Luminal B</td></tr><tr><td align="left" valign="bottom">Metastasis</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Patient 11</bold></td><td align="left" valign="bottom"><bold>Patient 12</bold></td><td align="left" valign="bottom"><bold>Patient 13</bold></td><td align="left" valign="bottom"><bold>Patient 14</bold></td><td align="left" valign="bottom"><bold>Patient 15</bold></td></tr><tr><td align="left" valign="bottom">Sex</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td></tr><tr><td align="left" valign="bottom">Age (years)</td><td align="char" char="." valign="bottom">62</td><td align="char" char="." valign="bottom">57</td><td align="char" char="." valign="bottom">41</td><td align="char" char="." valign="bottom">53</td><td align="char" char="." valign="bottom">58</td></tr><tr><td align="left" valign="bottom">T grade</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom">N grade</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Menopausal status</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Postmenopausal</td><td align="left" valign="bottom">Postmenopausal</td></tr><tr><td align="left" valign="bottom">Subclass</td><td align="left" valign="bottom">HER2 positive</td><td align="left" valign="bottom">HER2 positive</td><td align="left" valign="bottom">HER2 positive</td><td align="left" valign="bottom">HER2 positive</td><td align="left" valign="bottom">HER2 positive</td></tr><tr><td align="left" valign="bottom">Metastasis</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Patient 16</bold></td><td align="left" valign="bottom"><bold>Patient 17</bold></td><td align="left" valign="bottom"><bold>Patient 18</bold></td><td align="left" valign="bottom"><bold>Patient 19</bold></td><td align="left" valign="bottom"><bold>Patient 20</bold></td></tr><tr><td align="left" valign="bottom">Sex</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td></tr><tr><td align="left" valign="bottom">Age (years)</td><td align="char" char="." valign="bottom">50</td><td align="char" char="." valign="bottom">37</td><td align="char" char="." valign="bottom">35</td><td align="char" char="." valign="bottom">51</td><td align="char" char="." valign="bottom">55</td></tr><tr><td align="left" valign="bottom">T grade</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom">N grade</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Menopausal status</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Premenopausal</td><td align="left" valign="bottom">Postmenopausal</td></tr><tr><td align="left" valign="bottom">Subclasses</td><td align="left" valign="bottom">Triple negative</td><td align="left" valign="bottom">Triple negative</td><td align="left" valign="bottom">Triple negative</td><td align="left" valign="bottom">Triple negative</td><td align="left" valign="bottom">Triple negative</td></tr><tr><td align="left" valign="bottom">Metastasis</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr></tbody></table><table-wrap-foot><fn><p>HER2, human epidermal growth factor receptor 2.</p></fn></table-wrap-foot></table-wrap><p>To investigate the biological role and clinical and prognostic significance of RGS10 in breast cancer tissues, we used survival analyses. In breast cancer samples from the Kaplan–Meier plotter database, high <italic>RGS10</italic> mRNA level was associated with significantly improved DFS (p=0.0066; <xref ref-type="fig" rid="fig1">Figure 1D</xref>) and OS (p=0.027; <xref ref-type="fig" rid="fig1">Figure 1E</xref>). In surgically resected breast cancer tissues (n = 133), RGS10 protein expression level detected by immunohistochemistry (representative images shown in <xref ref-type="fig" rid="fig1">Figure 1F</xref>) was positively correlated with breast cancer subtype (p=0.043), distant metastasis (p=0.008), and survival status (p=0.024). There were no correlations with age, comorbid disease, histological grade, tumor size, number of positive axillary lymph nodes, number of pregnancies, number of births, age at first pregnancy, menopausal status, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 (HER2) status, or Ki67 status (<xref ref-type="table" rid="table2">Table 2</xref>). In these patients, a high RGS10 protein expression level was associated with a longer DFS (p<italic>=</italic>0.003, <xref ref-type="fig" rid="fig1">Figure 1G</xref>) and OS (p=0.022, <xref ref-type="fig" rid="fig1">Figure 1H</xref>). Clinicopathological characteristics associated with DFS and OS were identified with Cox regression analyses. On multivariate regression analysis, histological grade and RGS10 protein expression were independent predictors of DFS (<xref ref-type="table" rid="table3">Table 3</xref>). On univariate regression analysis, age, histological grade, and RGS10 protein expression were independent predictors of OS (<xref ref-type="table" rid="table4">Table 4</xref>). This suggests low RGS10 expression is associated with poor survival in patients with breast cancer.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Correlations between RGS10 expression and clinicopathological characteristics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Variable</th><th align="left" valign="top">RGS10 expression (n, %)</th><th align="left" valign="top">RGS10 expression (n, %)</th><th align="left" valign="top">p-Value</th></tr></thead><tbody><tr><td align="left" valign="top">No. of patients</td><td align="char" char="." valign="top">34 (25.6)</td><td align="char" char="." valign="top">99 (74.4)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Age (years)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.590</td></tr><tr><td align="char" char="." valign="top">≤45</td><td align="char" char="." valign="top">8 (23.5)</td><td align="char" char="." valign="top">28 (28.3)</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&gt;45</td><td align="char" char="." valign="top">26 (76.5)</td><td align="char" char="." valign="top">71 (71.7)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Other disease</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.746</td></tr><tr><td align="left" valign="top">Yes</td><td align="char" char="." valign="top">28 (82.4)</td><td align="char" char="." valign="top">79 (79.8)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No</td><td align="char" char="." valign="top">6 (17.6)</td><td align="char" char="." valign="top">20 (20.2)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Histological grade</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.744</td></tr><tr><td align="left" valign="top">I</td><td align="char" char="." valign="top">12 (35.3)</td><td align="char" char="." valign="top">30 (30.3)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">II</td><td align="char" char="." valign="top">19 (55.9)</td><td align="char" char="." valign="top">56 (56.6)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">III</td><td align="char" char="." valign="top">3 (8.8)</td><td align="char" char="." valign="top">13 (13.1)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Tumor size (cm)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.101</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">2.191 (1.0–8.0)</td><td align="char" char="." valign="top">1.861 (0.6–4.0)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>No. of positive axillary lymph nodes</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.316</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">1.06 (0–19)</td><td align="char" char="." valign="top">1.93 (0–27)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>No. of pregnancies</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.706</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">2.50 (1–6)</td><td align="char" char="." valign="top">2.40 (0–7)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>No. of births</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.497</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">1.62 (1–3)</td><td align="char" char="." valign="top">1.75 (0–7)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Age at first pregnancy (years)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.489</td></tr><tr><td align="char" char="." valign="top">&lt;21</td><td align="char" char="." valign="top">1 (2.9)</td><td align="char" char="." valign="top">6 (6.1)</td><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">21–25</td><td align="char" char="." valign="top">15 (44.1)</td><td align="char" char="." valign="top">42 (42.4)</td><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">26–30</td><td align="char" char="." valign="top">18 (52.9)</td><td align="char" char="." valign="top">46 (46.5)</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&gt;30</td><td align="char" char="." valign="top">0 (0)</td><td align="char" char="." valign="top">5 (5.0)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Menopausal status</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.216</td></tr><tr><td align="left" valign="top">Premenopausal</td><td align="char" char="." valign="top">21 (61.8)</td><td align="char" char="." valign="top">49 (49.5)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Postmenopausal</td><td align="char" char="." valign="top">13 (38.2)</td><td align="char" char="." valign="top">50 (50.5)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Estrogen receptor status</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.397</td></tr><tr><td align="left" valign="top">Positive</td><td align="char" char="." valign="top">25 (73.5)</td><td align="char" char="." valign="top">65 (65.7)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Negative</td><td align="char" char="." valign="top">9 (26.5)</td><td align="char" char="." valign="top">34 (34.3)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Progesterone receptor status</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.527</td></tr><tr><td align="left" valign="top">Positive</td><td align="char" char="." valign="top">25 (73.5)</td><td align="char" char="." valign="top">78 (78.8)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Negative</td><td align="char" char="." valign="top">9 (26.5)</td><td align="char" char="." valign="top">21 (21.2)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>HER2 status</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.496</td></tr><tr><td align="left" valign="top">Positive</td><td align="char" char="." valign="top">6 (17.6)</td><td align="char" char="." valign="top">23 (23.2)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Negative</td><td align="char" char="." valign="top">28 (82.4)</td><td align="char" char="." valign="top">76 (76.8)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Ki67 status</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.773</td></tr><tr><td align="char" char="." valign="top">&gt;20</td><td align="char" char="." valign="top">14 (41.2)</td><td align="char" char="." valign="top">38 (38.4)</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">≤20</td><td align="char" char="." valign="top">20 (58.8)</td><td align="char" char="." valign="top">61 (61.6)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Molecular type</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.043</td></tr><tr><td align="left" valign="top">Luminal A</td><td align="char" char="." valign="top">6 (17.6)</td><td align="char" char="." valign="top">30 (30.3)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Luminal B</td><td align="char" char="." valign="top">19 (55.9)</td><td align="char" char="." valign="top">36 (36.3)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">HER2+</td><td align="char" char="." valign="top">2 (5.9)</td><td align="char" char="." valign="top">16 (16.2)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Triple-negative breast cancer</td><td align="char" char="." valign="top">7 (20.6)</td><td align="char" char="." valign="top">17 (17.2)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Distant metastasis</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.008</td></tr><tr><td align="left" valign="top">Yes</td><td align="char" char="." valign="top">7 (20.6)</td><td align="char" char="." valign="top">46 (46.5)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No</td><td align="char" char="." valign="top">27 (79.4)</td><td align="char" char="." valign="top">53 (53.5)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Disease-free survival (months)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">&lt;0.001</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">114.71 (53–140)</td><td align="char" char="." valign="top">89.66 (9–132)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Death</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.024</td></tr><tr><td align="left" valign="top">Yes</td><td align="char" char="." valign="top">5 (14.7)</td><td align="char" char="." valign="top">35 (35.4)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No</td><td align="char" char="." valign="top">29 (85.3)</td><td align="char" char="." valign="top">64 (64.6)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Overall survival (months)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="char" char="." valign="top">0.030</td></tr><tr><td align="left" valign="top">Median (range)</td><td align="char" char="." valign="top">120.41 (80–140)</td><td align="char" char="." valign="top">107.64 (24–140)</td><td align="left" valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>HER2, human epidermal growth factor receptor 2.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Univariate and multivariate Cox regression analyses of clinicopathological risk factors for disease-free survival (DFS).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Variable</th><th align="left" valign="top"/><th align="left" valign="top">DFS</th><th align="left" valign="top"/><th align="left" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>Univariate analysis</bold></td><td align="left" valign="top"/><td align="left" valign="top"><bold>Multivariate analysis</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>HR (95% CI)</bold></td><td align="left" valign="top"><bold>p-Value</bold></td><td align="left" valign="top"><bold>HR (95% CI)</bold></td><td align="left" valign="top"><bold>p-Value</bold></td></tr><tr><td align="left" valign="top">Age (years)</td><td align="char" char="." valign="top">0.720 (0.400–1.296)</td><td align="char" char="." valign="top">0.273</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Other disease</td><td align="char" char="." valign="top">0.885 (0.445–1.762)</td><td align="char" char="." valign="top">0.728</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Histological grade</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">I</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.003</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.004</td></tr><tr><td align="left" valign="top">II</td><td align="char" char="." valign="top">2.636 (1.263–5.503)</td><td align="char" char="." valign="top">0.010</td><td align="char" char="." valign="top">2.704 (1.294–5.649)</td><td align="char" char="." valign="top">0.008</td></tr><tr><td align="left" valign="top">III</td><td align="char" char="." valign="top">4.638 (1.877–11.462)</td><td align="char" char="." valign="top">0.001</td><td align="char" char="." valign="top">4.566 (1.846–11.294)</td><td align="char" char="." valign="top">0.001</td></tr><tr><td align="left" valign="top">Tumor size (cm)</td><td align="char" char="." valign="top">1.065 (0.840–1.350)</td><td align="char" char="." valign="top">0.605</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of positive axillary lymph nodes</td><td align="char" char="." valign="top">1.012 (0.953–1.074)</td><td align="char" char="." valign="top">0.698</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of pregnancies</td><td align="char" char="." valign="top">0.835 (0.662–1.054)</td><td align="char" char="." valign="top">0.129</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of births</td><td align="char" char="." valign="top">0.694 (0.481–1.001)</td><td align="char" char="." valign="top">0.051</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Age at first pregnancy (years)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&lt;21</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.501</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">21–25</td><td align="char" char="." valign="top">3.336 (0.449–24.810)</td><td align="char" char="." valign="top">0.239</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">26–30</td><td align="char" char="." valign="top">3.886 (0.530–28.499)</td><td align="char" char="." valign="top">0.182</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&gt;30</td><td align="char" char="." valign="top">1.838 (0.115–29.429)</td><td align="char" char="." valign="top">0.667</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Menopausal status</td><td align="char" char="." valign="top">0.844 (0.492–1.451)</td><td align="char" char="." valign="top">0.540</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Estrogen receptor status</td><td align="char" char="." valign="top">1.534 (0.820–2.869)</td><td align="char" char="." valign="top">0.180</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Progesterone receptor status</td><td align="char" char="." valign="top">1.098 (0.577–2.089)</td><td align="char" char="." valign="top">0.776</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">HER2 status</td><td align="char" char="." valign="top">0.841 (0.433–1.635)</td><td align="char" char="." valign="top">0.610</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Ki67 status</td><td align="char" char="." valign="top">0.816 (0.465–1.431)</td><td align="char" char="." valign="top">0.478</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Molecular type</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Luminal A</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.307</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Luminal B</td><td align="char" char="." valign="top">1.940 (0.819–4.593)</td><td align="char" char="." valign="top">0.132</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">HER2+</td><td align="char" char="." valign="top">1.147 (0.479–2.747)</td><td align="char" char="." valign="top">0.758</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Triple-negative breast cancer</td><td align="char" char="." valign="top">1.453 (0.527–4.007)</td><td align="char" char="." valign="top">0.470</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">RGS10 expression</td><td align="char" char="." valign="top">0.323 (0.146–0.716)</td><td align="char" char="." valign="top">0.005</td><td align="char" char="." valign="top">0.321 (0.144–0.713)</td><td align="char" char="." valign="top">0.005</td></tr></tbody></table><table-wrap-foot><fn><p>HR, hazard ratio; HER2, human epidermal growth factor receptor 2; NA, not analyzed.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Univariate and multivariate Cox regression analyses of clinicopathological risk factors for overall survival.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Variable</th><th align="left" valign="top"/><th align="left" valign="top">Overall survival</th><th align="left" valign="top"/><th align="left" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>Univariate analysis</bold></td><td align="left" valign="top"/><td align="left" valign="top"><bold>Multivariate analysis</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>HR (95% CI)</bold></td><td align="left" valign="top"><bold>p-Value</bold></td><td align="left" valign="top"><bold>HR (95% CI)</bold></td><td align="left" valign="top"><bold>p-Value</bold></td></tr><tr><td align="left" valign="top">Age (years)</td><td align="char" char="." valign="top">0.423 (0.226–0.792)</td><td align="char" char="." valign="top">0.007</td><td align="char" char="." valign="top">0.305 (0.154–0.603)</td><td align="char" char="." valign="top">0.001</td></tr><tr><td align="left" valign="top">Other disease</td><td align="char" char="." valign="top">0.984 (0.453–2.136)</td><td align="char" char="." valign="top">0.967</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Histological grade</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">I</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.067</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.008</td></tr><tr><td align="left" valign="top">II</td><td align="char" char="." valign="top">1.519 (0.703–3.284)</td><td align="char" char="." valign="top">0.288</td><td align="char" char="." valign="top">1.834 (0.840–4.007)</td><td align="char" char="." valign="top">0.128</td></tr><tr><td align="left" valign="top">III</td><td align="char" char="." valign="top">3.062 (1.180–7.943)</td><td align="char" char="." valign="top">0.021</td><td align="char" char="." valign="top">5.090 (1.812–14.300)</td><td align="char" char="." valign="top">0.002</td></tr><tr><td align="left" valign="top">Tumor size (cm)</td><td align="char" char="." valign="top">1.045 (0.788–1.385)</td><td align="char" char="." valign="top">0.760</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of positive axillary lymph nodes</td><td align="char" char="." valign="top">1.011 (0.943–1.083)</td><td align="char" char="." valign="top">0.759</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of pregnancies</td><td align="char" char="." valign="top">0.941 (0.731–1.213)</td><td align="char" char="." valign="top">0.640</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">No. of births</td><td align="char" char="." valign="top">0.896 (0.625–1.285)</td><td align="char" char="." valign="top">0.550</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Age at first pregnancy (years)</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&lt;21</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.580</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">21–25</td><td align="char" char="." valign="top">2.818 (0.378–21.001)</td><td align="char" char="." valign="top">0.312</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="ndash" valign="top">26–30</td><td align="char" char="." valign="top">2.021 (0.269–15.190)</td><td align="char" char="." valign="top">0.494</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="char" char="." valign="top">&gt;30</td><td align="char" char="." valign="top">3.255 (0.295–35.934)</td><td align="char" char="." valign="top">0.335</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Menopausal status</td><td align="char" char="." valign="top">0.769 (0.405–1.458)</td><td align="char" char="." valign="top">0.420</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Estrogen receptor status</td><td align="char" char="." valign="top">0.769 (0.405–1.458)</td><td align="char" char="." valign="top">0.420</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Progesterone receptor status</td><td align="char" char="." valign="top">1.091 (0.519–2.293)</td><td align="char" char="." valign="top">0.818</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">HER2 status</td><td align="char" char="." valign="top">0.587 (0.246–1.398)</td><td align="char" char="." valign="top">0.229</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Ki67 status</td><td align="char" char="." valign="top">0.718 (0.370–1.392)</td><td align="char" char="." valign="top">0.327</td><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><italic>Molecular type</italic></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">NA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Luminal A</td><td align="left" valign="top"/><td align="char" char="." valign="top">0.589</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Luminal B</td><td align="char" char="." valign="top">0.639 (0.295–1.383)</td><td align="char" char="." valign="top">0.255</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">HER2+</td><td align="char" char="." valign="top">0.756 (0.272–2.100)</td><td align="char" char="." valign="top">0.592</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Triple-negative breast cancer</td><td align="char" char="." valign="top">1.079 (0.467–2.493)</td><td align="char" char="." valign="top">0.860</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">RGS10 expression</td><td align="char" char="." valign="top">0.353 (0.138–0.900)</td><td align="char" char="." valign="top">0.029</td><td align="char" char="." valign="top">0.364 (0.154–0.603)</td><td align="char" char="." valign="top">0.001</td></tr></tbody></table><table-wrap-foot><fn><p>HR, hazard ratio; HER2, human epidermal growth factor receptor 2; NA, not analyzed.</p></fn></table-wrap-foot></table-wrap><p>Taken together, these findings imply that RGS10 has a role in suppressing breast cancer and RGS10 may represent a potential prognostic biomarker in breast cancer.</p></sec><sec id="s2-2"><title><italic>RGS10</italic> silencing increases the proliferation and migration of breast cancer cells in vitro</title><p>To characterize RGS10 protein expression in the breast cancer cell lines MDA-MB-231, MCF7, and SKBR3, we conducted western blotting. <italic>MDA-</italic>MB<italic>-</italic>231 is a highly aggressive, invasive, and poorly differentiated triple-negative breast cancer cell line (<xref ref-type="bibr" rid="bib6">Bianchini et al., 2016</xref>). MCF7 is an adenocarcinoma cell line with estrogen, progesterone, and glucocorticoid receptors (<xref ref-type="bibr" rid="bib25">Lee et al., 2015</xref>). The SKBR3 cell line overexpresses the HER2/c-erb-2 gene product (<xref ref-type="bibr" rid="bib30">Merlin et al., 2002</xref>). RGS10 protein levels appeared lower in the highly aggressive cell line MDA-MB-231 compared to the poorly aggressive and less invasive cell lines MCF7 and SKBR3 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). This finding validates our previous observations suggesting that RGS10 acts as a tumor suppressor in breast cancer.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>RGS10</italic> silencing increases the proliferation and migration of breast cancer cells in vitro.</title><p>(<bold>A</bold>) Western blotting showing RGS10 protein levels in molecularly distinct breast cancer cell lines. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>. (<bold>B</bold>) Western blotting showing RGS10 protein levels in SKBR3 cells transfected with three independent shRNA constructs, shRNA-<italic>RGS10</italic>-161, shRNA-<italic>RGS10</italic>-321, and shRNA-<italic>RGS10</italic>-506, and shRNA-<italic>NC</italic>. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig2sdata6">Figure 2—source data 6</xref>. (<bold>C</bold>) CCK-8 assay showing the viability of SKBR3 cells transfected with shRNA-<italic>RGS10</italic>-161, shRNA-<italic>RGS10</italic>-506, or shRNA-<italic>NC</italic>. **p &lt;0.01, one-way ANOVA. (<bold>D–F</bold>) Colony formation (<bold>D</bold>) and transwell migration/invasion (<bold>E, F</bold>) assays in SKBR3 cells transfected with shRNA-<italic>RGS10</italic>-161, shRNA-<italic>RGS10</italic>-506, or shRNA-<italic>NC</italic>. ***p&lt;0.001, one-way ANOVA.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig2-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata6"><label>Figure 2—source data 6.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig2-data6-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2sdata7"><label>Figure 2—source data 7.</label><caption><title>Original files for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata8"><label>Figure 2—source data 8.</label><caption><title>Original files for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata9"><label>Figure 2—source data 9.</label><caption><title>Original files for <xref ref-type="fig" rid="fig2">Figure 2E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata10"><label>Figure 2—source data 10.</label><caption><title>Original files for <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig2-data10-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig2-v1.tif"/></fig><p>To investigate the role of RGS10 in breast cancer cells, we silenced <italic>RGS10</italic> in SKBR3 cells using two independent shRNA constructs, shRNA-<italic>RGS10</italic>-161 and shRNA-<italic>RGS10</italic>-506, which had significantly improved transfection efficiency compared to shRNA-<italic>RGS10</italic>-321 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). We evaluated the effects of RGS10 on breast cancer cell proliferation, colony formation, migration, and invasion in <italic>RGS10</italic>-depleted (shRNA-<italic>RGS10</italic>-506, shRNA-<italic>RGS10</italic>-161) SKBR3 cells and SKBR3 cells transfected with shRNA-negative control (NC). Cell Counting Kit-8 (CCK-8) analysis, colony formation, and transwell migration/invasion assays showed significantly increased proliferative ability, clonogenic ability, migration ability, and invasive capacity in <italic>RGS10</italic>-depleted SKBR3 cells compared to NC (p&lt;0.001) (<xref ref-type="fig" rid="fig2">Figure 2C–F</xref>).</p><p>These findings show invasion and metastasis were enhanced in breast cancer cells lacking <italic>RGS10</italic>, suggesting an inhibitory effect of RGS10 in breast cancer metastasis.</p></sec><sec id="s2-3"><title><italic>RGS10</italic> silencing promotes lipocalin-2 (LCN2) expression and EMT in breast cancer cells</title><p>To explore the mechanisms by which RGS10 suppresses breast cancer invasion and metastasis, we analyzed potential downstream tumor metastasis-related genes by comparing the transcriptomes in <italic>RGS10</italic>-depleted (shRNA-<italic>RGS10</italic>-506, shRNA-<italic>RGS10</italic>-161) SKBR3 cells and SKBR3 cells transfected with shRNA-NC. Differential gene expression was visualized using a volcano plot, which revealed that 70 genes were significantly upregulated in <italic>RGS10</italic>-depleted SKBR3 cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) enrichment analysis of differentially expressed genes identified upregulated KEGG pathways, biological processes, cellular components, and molecular functions (<xref ref-type="fig" rid="fig4">Figure 4B–E</xref>). Upregulated KEGG pathways were associated with cytokine–cytokine receptor interactions and extracellular matrix–receptor interactions. Gene sets associated with high- and low-<italic>RGS10</italic> mRNA expression were identified by gene set enrichment analysis using the Molecular Signatures Database (<xref ref-type="bibr" rid="bib28">Liberzon et al., 2011</xref>). Gene sets associated with high-<italic>RGS10</italic> mRNA expression included allograft rejection, apoptosis, interleukin (IL) 6/Janus kinase/signal transducer and activator of transcription pathway (STAT) 3, IL2/STAT5 pathway, and inflammatory response (<xref ref-type="table" rid="table5">Table 5</xref>). Western blotting showed changes in biomarkers of EMT in <italic>RGS10</italic>-depleted SKBR3 cells compared to NC. Neutrophil-derived cytokine LCN2 and vimentin protein levels were higher and E-cadherin protein levels were lower in <italic>RGS10</italic>-depleted SKBR3 cells compared to NC (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Protein–protein network interaction network and Gene Ontology (GO) functional- and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway-enrichment analysis of genes co-expressed with RGS10.</title><p>(<bold>A</bold>) Volcano plot showing differentially expressed genes between SKBR3 cells transfected with shRNA-<italic>RGS10</italic> or shRNA-<italic>NC</italic>. (<bold>B–E</bold>) KEGG pathway analysis and GO enrichment analysis of differentially expressed genes showing the ten most enriched terms. BP: biological processes; MF: molecular function; CC: cellular compartment. (<bold>F</bold>) LCN2, E-cadherin, and vimentin protein levels in SKBR3 cells transfected with shRNA-<italic>RGS10</italic> or shRNA-<italic>NC</italic>. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>. (<bold>G</bold>) Schematics of predicted <italic>MIR539-5p</italic> binding sites between wild-type and mutant RGS10 sequences in the 3ʹ-untranslated regions. (<bold>H</bold>) Relative luciferase activities detected after cotransfection of wild-type or mutant luciferase reporter plasmids and an <italic>MIR539</italic>-mimic.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig3-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Original files for <xref ref-type="fig" rid="fig3">Figure 3A–E, G and H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig3-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig3-v1.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>MIR539-5p</italic> regulates the migration, invasion, proliferation, and epithelial–mesenchymal transition (EMT) of breast cancer cells.</title><p>(<bold>A</bold>) qPCR showing the transfection efficiency of the <italic>MIR539-5p</italic> mimic. ***p&lt;0.001, one-way ANOVA. (<bold>B, C</bold>) qRT-PCR and western blotting showing <italic>RGS10</italic> mRNA and protein levels in SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic, negative control (NC), or wild type (WT). ***p&lt;0.001, one-way ANOVA. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>. (<bold>D</bold>) CCK-8 assay showing the viability of SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic, NC, or WT. ***p&lt;0.001, one-way ANOVA. (<bold>E–G</bold>) Colony formation (<bold>E</bold>) and transwell migration/invasion (<bold>F, G</bold>) assays in SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic, NC, or WT. *p&lt;0.05, **p&lt;0.01, Student’s <italic>t</italic>-test. (<bold>H</bold>) Western blotting showing protein levels of LCN2 and biomarkers of EMT in SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic or NC. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig4sdata4">Figure 4—source data 4</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig4sdata5">Figure 4—source data 5</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig4sdata6">Figure 4—source data 6</xref>. (<bold>I</bold>) Immunofluorescence staining showing E-cadherin, vimentin, and snail protein expression in SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic or NC. Scale bar: 50 µm.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig4-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig4">Figure 4H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig4">Figure 4H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig4">Figure 4H</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig4-data6-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Original files for <xref ref-type="fig" rid="fig4">Figure 4A, B and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Original files for <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Original files for <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata10"><label>Figure 4—source data 10.</label><caption><title>Original files for <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data10-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata11"><label>Figure 4—source data 11.</label><caption><title>Original files for <xref ref-type="fig" rid="fig4">Figure 4I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig4-data11-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig4-v1.tif"/></fig><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Gene sets enriched in phenotype ‘high’.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">MSigDB collection</th><th align="left" valign="top">Gene set name</th><th align="left" valign="top">NES</th><th align="left" valign="top">NOMp-value</th><th align="left" valign="top">FDR q-value</th></tr></thead><tbody><tr><td align="left" valign="top">h.all.v6.2.symbols.gmt [Hallmarks]</td><td align="left" valign="top">HALLMARK_ALLOGRAFT_REJECTION</td><td align="char" char="." valign="top">–2.55</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_APOPTOSIS</td><td align="char" char="." valign="top">–2.41</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_IL6_JAK_STAT3_SIGNALING</td><td align="char" char="." valign="top">–2.40</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_IL2_STAT5_SIGNALING</td><td align="char" char="." valign="top">–2.39</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_INFLAMMATORY_RESPONSE</td><td align="char" char="." valign="top">–2.37</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_INTERFERON_GAMMA_RESPONSE</td><td align="char" char="." valign="top">–2.33</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_COMPLEMENT</td><td align="char" char="." valign="top">–2.27</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_KRAS_SIGNALING_UP</td><td align="char" char="." valign="top">–2.25</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_INTERFERON_ALPHA_RESPONSE</td><td align="char" char="." valign="top">–2.22</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">HALLMARK_APICAL_JUNCTION</td><td align="char" char="." valign="top">–2.13</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr></tbody></table><table-wrap-foot><fn><p>Gene sets with NOM p-value &lt;0.05 and FDR q-value &lt;0.25 were considered as significant.</p></fn><fn><p>MSigDB, Molecular Signatures Database; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.</p></fn></table-wrap-foot></table-wrap><p>These findings show that <italic>RGS10</italic> deficiency promotes invasion and metastasis by activating the LCN2 pathway to induce EMT in breast cancer cells, supporting the potential of RGS10 as a prognostic biomarker in breast cancer.</p></sec><sec id="s2-4"><title><italic>MIR539-5p</italic> regulates the migration, invasion, proliferation, and EMT of breast cancer cells</title><p>To study the upstream regulatory mechanism of <italic>RGS10</italic> in breast cancer, we used the StarBase database to predict miRNAs that could potentially bind to <italic>RGS10</italic>. The luciferase reporter assay identified <italic>MIR539-5p</italic> as a miRNA that targets <italic>RGS10</italic> in breast cancer cells (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>).</p><p>To predict the potential effects of <italic>MIR539-5p</italic> on breast cancer cells, we transfected SKBR3 and MDA-MB-231 cells with a <italic>MIR539-5p</italic> mimic to represent <italic>MIR539-5p</italic> overexpression, a <italic>MIR539-5p</italic> inhibitor, or appropriate NCs (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). RT-qPCR and western blotting validated transfection efficiency and showed that <italic>RGS10</italic> mRNA and protein levels were significantly decreased in SKBR3 cells overexpressing <italic>MIR539-5p</italic> compared to SKBR3 cells transfected with <italic>miRNA-</italic>NC or the wild type (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). CCK-8 analysis, and colony formation and transwell migration/invasion assays showed SKBR3 cell proliferation, colony formation, migration, and invasion were significantly increased in SKBR3 cells overexpressing <italic>MIR539-5p</italic> compared to SKBR3 cells transfected with <italic>miRNA-NC</italic> or the wild type (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>). In contrast, RGS10 protein levels were significantly increased (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>) and MDA-MB-231 cell proliferation, colony formation, migration, and invasion were significantly decreased in MDA-MB-231 cells transfected with <italic>MIR539-5p</italic> inhibitor compared to anti-<italic>miRNA-NC</italic> or the wild type (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>MIR539-5p</italic> inhibitor suppresses breast cancer cell proliferation and invasion.</title><p>(<bold>A</bold>) qPCR showing transfection efficiency of the <italic>MIR539-5p</italic> inhibitor after 48 hr. ***p&lt;0.001, one-way ANOVA. (<bold>B, C</bold>) qRT-PCR and western blotting showing <italic>RGS10</italic> mRNA and protein levels in MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor, negative control (NC), or wild type (WT). ***p&lt;0.001, one-way ANOVA. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>. (<bold>D</bold>) CCK-8 assay showing the viability of MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor, NC, or WT. ***p&lt;0.001, one-way ANOVA. (<bold>E–G</bold>) Colony formation (<bold>E</bold>) and transwell migration/invasion (<bold>F, G</bold>) assays in MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor, NC, or WT. *p&lt;0.05, **p&lt;0.01, Student’s <italic>t</italic>-test. (<bold>H</bold>) Western blotting showing protein levels of LCN2 and biomarkers of EMT in MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor or NC. The original files of the full raw unedited blots are provided in <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>. The uncropped gels with the relevant bands labeled are provided in <xref ref-type="supplementary-material" rid="fig5sdata5">Figure 5—source data 5</xref>. The statistical data is provided in <xref ref-type="supplementary-material" rid="fig5sdata6">Figure 5—source data 6</xref>. (<bold>I</bold>) Immunofluorescence staining showing E-cadherin, vimentin, and snail protein expression in MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor or <italic>NC</italic>. Scale bar: 50 µm.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig5-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-97327-fig5-data6-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata7"><label>Figure 5—source data 7.</label><caption><title>Original files for <xref ref-type="fig" rid="fig5">Figure 5A, B and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata8"><label>Figure 5—source data 8.</label><caption><title>Original files for <xref ref-type="fig" rid="fig5">Figure 5E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata9"><label>Figure 5—source data 9.</label><caption><title>Original files for <xref ref-type="fig" rid="fig5">Figure 5F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata10"><label>Figure 5—source data 10.</label><caption><title>Original files for <xref ref-type="fig" rid="fig5">Figure 5G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data10-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata11"><label>Figure 5—source data 11.</label><caption><title>Original files for <xref ref-type="fig" rid="fig5">Figure 5I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig5-data11-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig5-v1.tif"/></fig><p>Based on these findings, for the first time, we propose a <italic>MIR539-5p</italic>/RGS10/LCN2 regulatory axis in breast cancer. Consistent with this, western blotting and immunofluorescence assays showed decreased E-cadherin protein expression and increased LCN2, vimentin, and snail protein expression in SKBR3 cells overexpressing <italic>MIR539-5p</italic> compared to SKBR3 cells transfected with <italic>miRNA-NC</italic> or the wild type (<xref ref-type="fig" rid="fig4">Figure 4H and I</xref>). These effects were reversed in MDA-MB-231 cells transfected with a <italic>MIR539-5p</italic> inhibitor compared to anti-<italic>miRNA-NC</italic> or the wild type (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>).</p><p>These findings identify <italic>MIR539-5p</italic> as a critical factor in breast cancer metastasis by regulating RGS10/LCN2 expression.</p></sec><sec id="s2-5"><title>RGS10 inhibits breast cancer growth by targeting LCN2 in vivo</title><p>To investigate tumorigenicity, we subcutaneously transplanted SKBR3 cells transfected with shRNA<italic>-RGS10</italic>-506 or shRNA<italic>-NC</italic> into nude mice. The growth of tumors derived from <italic>RGS10</italic>-depleted SKBR3 cells was significantly increased compared to NC, manifested by larger tumor size compared to NC (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). Immunohistochemistry showed LCN2, snail, and vimentin protein expression were increased and E-cadherin protein expression was decreased in tumor tissues derived from <italic>RGS10</italic>-depleted SKBR3 cells compared to NC (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>RGS10 inhibits breast cancer growth by targeting LCN2 in vivo.</title><p>(<bold>A</bold>) Size of tumors derived from <italic>RGS10</italic>-depleted SKBR3 cells, negative control (NC), and wild type (WT). (<bold>B</bold>) Volume of tumors derived from <italic>RGS10</italic>-depleted SKBR3 cells, NC, and WT. ***p&lt;0.001, one-way ANOVA. (<bold>C</bold>) Hematoxylin and eosin staining of tumors derived from <italic>RGS10</italic>-depleted SKBR3 cells and NC. (<bold>D</bold>) Immunohistochemical staining showing LCN2, E-cadherin, snail, and vimentin protein expression in tumors derived from <italic>RGS10</italic>-depleted SKBR3 cells and NC.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Uncropped gels with the relevant bands labeled in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig6-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97327-fig6-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-fig6-v1.tif"/></fig><p>These in vivo data confirm the previous in vitro observations that <italic>RGS10</italic> deficiency promotes invasion and metastasis by activating the LCN2 pathway to induce EMT in breast cancer cells, and demonstrate that RGS10 has utility as a prognostic biomarker in breast cancer.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Distant metastasis is a main cause of death in patients with breast cancer. Identification of prognostic biomarkers for early distant metastasis may inform clinical decision-making and improve patient outcomes. To the best of our knowledge, this is the first study to characterize the role of RGS10 as a tumor suppressor and biomarker of EMT in breast cancer. RGS10 was expressed at lower levels in breast cancer tissues than in adjacent normal breast tissues. RGS10 expression was associated with molecular subtypes of breast cancer, distant metastasis, and survival status. Patients with high compared to low <italic>RGS10</italic> mRNA expression in breast cancer tissues had improved DFS and OS. RGS10 protein levels were lower in the highly aggressive breast cancer cell line MDA-MB-231 compared to the poorly aggressive and less invasive breast cancer cell lines MCF7 and SKBR3. RGS10 reduced breast cancer cell proliferation, colony formation, invasion, and migration by inhibiting EMT via a novel mechanism dependent on LCN2 and <italic>MIR539-5p.</italic></p><p>EMT is involved in normal development and morphogenic processes, including embryogenesis and tissue regeneration. Pathological EMT promotes invasion and metastasis in tumors through intracellular signaling, transcription factors, miRNAs, and epigenetic and posttranslational regulators (<xref ref-type="bibr" rid="bib21">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="bib24">Lamouille et al., 2014</xref>). Signaling pathways such as TGF-β, Wnt, Notch, and phosphoinositide 3-kinase/AKT contribute to EMT, often with cross-talk at various levels and feedback activation/repression mechanisms (<xref ref-type="bibr" rid="bib13">Deshmukh et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Huang et al., 2022</xref>). Transcription factors such as snail, slug, ZEBl/ZEB2, and Twist1/Twist2 induce EMT by acting on the E-box sequence of the CDH1 promoter. Noncoding miRNAs regulate EMT by selectively targeting mRNAs of cell receptors, signaling pathways, the cell cycle, or cell adhesion (<xref ref-type="bibr" rid="bib14">Górecki and Rak, 2021</xref>; <xref ref-type="bibr" rid="bib21">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Li et al., 2019</xref>). Epigenetic modifications, including DNA methylation and histone modifications, alter the expression of EMT transcription factors involved in the molecular pathways of metabolism, transcription, differentiation, and apoptosis (<xref ref-type="bibr" rid="bib14">Górecki and Rak, 2021</xref>).</p><p>The present study identifies RGS10 as an important mediator of EMT in breast cancer. Previous studies have demonstrated links between several RGS proteins and various cancers, with RGS proteins acting as tumor initiators or suppressors depending on the RGS protein and type of cancer (<xref ref-type="bibr" rid="bib27">Li et al., 2023</xref>). RGS10 is the smallest protein of the RGS D/12 subfamily, which functions as GAPs for the Gi family Gα subunits (<xref ref-type="bibr" rid="bib2">Almutairi et al., 2020</xref>). RGS10 has been linked to a poor prognosis in patients with laryngeal cancer (<xref ref-type="bibr" rid="bib46">Yin et al., 2013</xref>), liver cancer (<xref ref-type="bibr" rid="bib43">Wen et al., 2015</xref>), and childhood acute myeloid leukemia (<xref ref-type="bibr" rid="bib10">Chaudhury et al., 2018</xref>). RGS10 may represent a biomarker of clinical staging for ovarian cancer and is one of five signature genes involved in the occurrence and development of ovarian cancer. This five-gene signature (<italic>RGS11</italic>, <italic>RGS10</italic>, <italic>RGS13</italic>, <italic>RGS4</italic>, and <italic>RGS3</italic>) is overexpressed in ovarian cancer and involved in extracellular matrix–receptor interaction, the TGF-β signaling pathway, the Wnt signaling pathway, and the chemokine signaling pathway. These pathways mediate the proliferation, migration, and invasion of ovarian cancer cells; in particular, TGF-β signaling plays an important role in EMT in ovarian cancer (<xref ref-type="bibr" rid="bib20">Hu et al., 2021</xref>).</p><p>The novel action of RGS10 in EMT in breast cancer appears to be dependent on LNC2, also known as neutrophil gelatinase-associated lipocalin, siderocalin, uterocalin, and oncogene 24p3. LNC2 is a secreted glycoprotein of the adipokine superfamily. LCN2 expression levels are particularly high in breast, pancreatic, ovarian, colorectal, thyroid, and bile duct cancer tissues and tumor cell lines. Previous studies show LCN2 can promote tumorigenesis by increasing invasion, metastasis, and proliferation while decreasing apoptosis, possibly because LCN2 can facilitate iron intake to cancer cells and form a heterodimer with matrix metalloproteinase-9 (<xref ref-type="bibr" rid="bib36">Santiago-Sánchez et al., 2020</xref>). In breast cancer, LCN2 can promote progression by inducing EMT through the estrogen receptor alpha/Slug axis (<xref ref-type="bibr" rid="bib33">Morales-Valencia et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Yang et al., 2009</xref>).</p><p>The regulation of EMT in breast cancer by RGS10 may rely on upstream regulation by <italic>MIR539-5p</italic>. miRNAs play a critical role in the cellular processes of breast cancer, including EMT (<xref ref-type="bibr" rid="bib47">Zhang et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Zhao et al., 2017</xref>). Previous reports indicate that <italic>MIR539</italic> expression is downregulated in breast cancer tissues and cell lines (<xref ref-type="bibr" rid="bib16">Guo et al., 2018</xref>), and <italic>MIR539</italic> acts as a tumor suppressor by targeting epidermal growth factor receptor (<xref ref-type="bibr" rid="bib16">Guo et al., 2018</xref>), specificity protein 1 (<xref ref-type="bibr" rid="bib8">Cai et al., 2020</xref>), or laminin subunit alpha 4 (<xref ref-type="bibr" rid="bib8">Cai et al., 2020</xref>) expression. In patients with breast cancer, decreased expression of <italic>MIR539</italic> was significantly associated with lymph node metastasis. In breast cancer cells, overexpression of <italic>MIR539</italic> inhibited the proliferation and promoted apoptosis of breast cancer cells, suppressed EMT, and sensitized cells to cisplatin treatment (<xref ref-type="bibr" rid="bib8">Cai et al., 2020</xref>). Further studies are required to fully elucidate miRNA regulation of the gene expression networks that are essential to EMT in breast cancer.</p><p>Inflammation promotes EMT in tumors, and EMT induces the production of proinflammatory factors by cancer cells (<xref ref-type="bibr" rid="bib39">Suarez-Carmona et al., 2017</xref>). The present study showed that RGS10 expression in SKBR3 cells was associated with the inflammatory response. Previous reports show that RGS10 regulates cellular physiology and fundamental signaling pathways in microglia, macrophages, and T-lymphocytes. In microglia and ovarian cancer cells, RGS10 regulates inflammatory signaling by a G protein-independent mechanism, linking RGS10 to the inflammatory signaling mediators tumor necrosis factor-alpha (TNFα) and cyclooxygenase-2 (<xref ref-type="bibr" rid="bib3">Alqinyah et al., 2018</xref>). In macrophages, RGS10 regulates activation and polarization by suppressing the production of the inflammatory cytokines TNFα and IL6 (<xref ref-type="bibr" rid="bib12">Dean and Hooks, 2020</xref>). These findings suggest a potential role for RGS10 in the development of an inflamed and immunosuppressive tumor microenvironment, which may have important implications for the progression in breast cancer (<xref ref-type="bibr" rid="bib39">Suarez-Carmona et al., 2017</xref>).</p><p>Our study had some limitations. First, this was a retrospective study with a small sample size. Thus, the conclusions should be confirmed in meta-analyses or large randomized controlled trials. Second, the mechanism by which the <italic>MIR539-5p</italic>/RGS10/LCN2 axis may be related to outcomes in patients with breast cancer remains to be elucidated. Biochemical characterization of the molecular mechanisms of RGS10 in breast cancer should provide additional insight into the potential of RGS10 as a biomarker of EMT, metastasis, and prognosis in breast cancer and the role of RGS10 as a therapeutic target.</p><p>In conclusion, the results of this study show that RGS10 expression is related to survival outcomes in patients with breast cancer. RGS10 protein levels were lower in the highly aggressive breast cancer cell line MDA-MB-231 compared to the poorly aggressive and less invasive breast cancer cell lines MCF7 and SKBR3. Silencing <italic>RGS10</italic> expression effectively increased the proliferation, colony formation, invasion, and migration ability of SKBR3 cells. The <italic>MIR539-5p</italic>/RGS10/LCN2 pathway was identified as an important regulatory axis of EMT in breast cancer. These data demonstrate that RGS10 may play a tumor suppressor role and be considered a biomarker of EMT and prognosis in breast cancer.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Sourceor reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (SKBR3)</td><td align="left" valign="bottom">HER2+ breast cancer cell line</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line cultured in McCoy’s 5A<break/>Culture medium supplemented with 10% FBS</td></tr><tr><td align="left" valign="bottom">Cell line (MCF-7)</td><td align="left" valign="bottom">ER+/PR+ breast cancer cell line</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line cultured in DMEM high glucose<break/>Culture medium supplemented with 10% FBS</td></tr><tr><td align="left" valign="bottom">Cell line (MDA-MB-<break/>231)</td><td align="left" valign="bottom">Triple-negative breast cancer cell line</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line cultured in L-15<break/>Culture medium supplemented with 10% FBS</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">RGS10 shRNA#161,321,506</td><td align="left" valign="bottom">Syngentech Biotechnology</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral construct to transfect and express the shRNA</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">MIRNA-539-5p mimics and inhibitor</td><td align="left" valign="bottom">GenePharma<break/>Biotechnology</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-<break/>RGS10 (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab154172</td><td align="left" valign="bottom">WB (1:250)<break/>IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- lipocalin-2 (rabbit monoclonal)</td><td align="left" valign="bottom">ABclonal</td><td align="left" valign="bottom">Cat#<break/>A2092</td><td align="left" valign="bottom">WB (1:1000)<break/>IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-<break/>E-cadherin<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat#<break/>20874-1-AP</td><td align="left" valign="bottom">WB (1:1000)<break/>IHC (1:500)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-vimentin<break/>(mouse monoclonal)</td><td align="left" valign="bottom">HUABIO</td><td align="left" valign="bottom">Cat#<break/>EM0401</td><td align="left" valign="bottom">WB (1:1000)<break/>IHC (1:200)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-snail<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">ABclonal</td><td align="left" valign="bottom">Cat#<break/>A5243</td><td align="left" valign="bottom">WB (1:1000)<break/>IHC (1:00)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">Cat#<break/>5174</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-<break/>β-tubulin (rabbit monoclonal)</td><td align="left" valign="bottom">ABclonal</td><td align="left" valign="bottom">Cat#<break/>AC008</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RGS10</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CACGACAGCGATGGCAGTTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RGS10</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTTTTCACGCCTTCTGGGTCTTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>MIR539-5p</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CGCTGCATGGAGAAATTATCCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>MIR539-5p</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGTGCAGGGTCCGAGGT</named-content></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SPSS</td><td align="left" valign="bottom">SPSS</td><td align="left" valign="bottom">SPSS, version 25.0<break/>Armonk, NY</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Bioinformatics</title><p>The Genotype-Tissue Expression database (<ext-link ext-link-type="uri" xlink:href="https://www.gtexportal.org/home/">https://www.gtexportal.org/home/</ext-link>) was used to analyze <italic>RGS10</italic> mRNA levels in 31 normal human tissues. The Cancer Cell Line Encyclopedia database (<ext-link ext-link-type="uri" xlink:href="https://sites.broadinstitute.org/ccle">https://sites.broadinstitute.org/ccle</ext-link>) was used to analyze <italic>RGS10</italic> mRNA levels in a series of cell lines (<xref ref-type="bibr" rid="bib35">Rahman et al., 2019</xref>). The Kaplan–Meier plotter (<ext-link ext-link-type="uri" xlink:href="http://kmplot.com">http://kmplot.com</ext-link>) was used to assess the relevance of <italic>RGS10</italic> mRNA expression for disease-free survival (DFS) and overall survival (OS) in patients with breast cancer (<xref ref-type="bibr" rid="bib17">Győrffy, 2021</xref>).</p></sec><sec id="s4-2"><title>Clinical specimens</title><p>This study included an additional 153 patients with histologically confirmed invasive ductal breast carcinoma who received treatment at the Shengjing Hospital of China Medical University from April 2006 to April 2008. Patients had (1) undergone surgery with no distant metastases at the time of the operation; (2) received standard adjuvant therapy after surgery; (3) ≥10 axillary lymph nodes dissected and examined pathologically after surgery (<xref ref-type="bibr" rid="bib11">Coates et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Gradishar et al., 2021</xref>; <xref ref-type="bibr" rid="bib44">Wolff et al., 2013</xref>); and (4) ≥10 years of follow-up as outpatients or by telephone interviews.</p><p>Twenty paired breast cancer and normal adjacent tissues were obtained from patients undergoing surgical resection at Shengjing Hospital of China Medical University to evaluate the status of RGS10. Clinical specimens from 133 patients were used to assess the effect of RGS10 on prognosis. The clinicopathological characteristics of these 153 patients are shown in <xref ref-type="table" rid="table1">Tables 1</xref> and <xref ref-type="table" rid="table2">2</xref>.</p><p>The study was approved by the Institutional Ethics Committee of Shengjing Hospital of China Medical University (Permit Number: 2024PS171K) and complied with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the National Medical Products Administration of China. Informed consent was obtained from all the participants.</p></sec><sec id="s4-3"><title>Breast cancer cells and culture</title><p>Human breast cancer cell lines SKBR3, MCF-7, and MDA-MB-231 were obtained from American Type Culture Collection (ATCC, Manassas, VA). The identity of cell lines had been authenticated by using STR profiling and with no contamination in the mycoplasma test. SKBR3 cells were cultured in McCoy’s 5A (modified) medium supplemented with 10% fetal bovine serum at 37°C and 5% CO<sub>2</sub>. MCF7 cells were cultured in DMEM high glucose (Invitrogen) medium supplemented with 10% fetal bovine serum at 37°C and 5% CO<sub>2</sub>. MDA-MB-231 cells were cultured in Leibovitz’s L-15 medium supplemented with 10% fetal bovine serum at 37°C without CO<sub>2</sub>.</p></sec><sec id="s4-4"><title>Transfection</title><p>SKBR3 cells were transfected with short hairpin (sh)RNAs specifically targeting <italic>RGS10</italic> (Syngentech Biotechnology, Beijing, China). shRNA sequences were: shRNA-<italic>RGS10</italic>-161, <italic>5′-<named-content content-type="sequence">GCCTCAAGAGCACAGCCAAAT</named-content>-3′</italic>; shRNA-<italic>RGS10</italic>-321, <italic>5′- <named-content content-type="sequence">GGAGATCTACATGACCTTTCT</named-content>-3′</italic>; and shRNA-<italic>RGS10</italic>-506, <italic>5′-<named-content content-type="sequence">GCACCCTCTGATGTTCCAGAA</named-content>-3′</italic>. The shRNA-NC sequence was <italic>5′-<named-content content-type="sequence">AAACGTGACACGTTCGGAGAA</named-content>-3′</italic>. As transfection efficiencies of shRNA-<italic>RGS10</italic>-161 and shRNA-<italic>RGS10</italic>-506 were better than shRNA-<italic>RGS10</italic>-321, shRNA-<italic>RGS10</italic>-161 and shRNA-<italic>RGS10</italic>-506 were used for subsequent experiments.</p><p>A <italic>MIR539-5p</italic> mimic, <italic>MIR539-5p</italic> inhibitor, and corresponding NC were designed and synthesized by GenePharma Biotechnology (Shanghai, China). The sequences of miRNA were <italic>MIR539-5p</italic> mimic, <italic>5′-<named-content content-type="sequence">GGAGAAAUUAUCCUUGGUGUGU</named-content>-3′; MIR539-5p</italic> mimic NC, <italic>5′-<named-content content-type="sequence">UUCUCCGAACGUGUCACGUTT</named-content>-3′; MIR539-5p</italic> inhibitor, <italic>5′-<named-content content-type="sequence">ACACACCAAGGA</named-content>UAAUUUCUCC-3′; MIR539-5p</italic> inhibitor NC 5′-CAGUACUUUUGUGUAGUACAA′. SKBR3 cells were transfected with the <italic>MIR539-5p</italic> mimic or NC. MDA-MB-231 cells were transfected with the <italic>MIR539-5p</italic> inhibitor or NC. Lipofectamine 3000 (L3000015, Thermo Fisher Scientific, Invitrogen, USA) was used for cell transfection.</p></sec><sec id="s4-5"><title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title><p>Total RNA was isolated from breast cancer tissues and breast cancer cell lines using Triquick reagent (Solarbio Life Science, Beijing, China) and reverse-transcribed using a cDNA synthesis kit (Takara Bio, Kusatsu, Japan). RT-qPCR was conducted using SYBR Green PCR Master Mix (TaKaRa) on a Real-time PCR System. Primers were <italic>RGS10</italic> forward, <italic>5′-<named-content content-type="sequence">CACGACAGCGATGGCAGTTCC</named-content>-3′; RGS10</italic> reverse, <italic>5′-<named-content content-type="sequence">CTTTTCACGCCTTCTGGGTCTTCC</named-content>-3′; GAPDH</italic> forward, <italic>5′-<named-content content-type="sequence">CCTTCCGTGTCCCCACT</named-content>-3′</italic>; and <italic>GAPDH</italic> reverse, <italic>5′-<named-content content-type="sequence">GCCTGCTTCACCACCTTC</named-content>-3ʹ</italic>. Thermocycling conditions were 95°C for 30 s, 40 cycles of 95°C for 3 s, and 60°C for 30 s. Relative mRNA levels were calculated using the comparative threshold (Cq) cycle method (2<sup>-ΔΔCt</sup>) (<xref ref-type="bibr" rid="bib1">Adnan et al., 2011</xref>).</p><p>cDNA synthesis in SKBR3 cells transfected with the <italic>MIR539-5p</italic> mimic or NC and MDA-MB-231 cells transfected with the <italic>MIR539-5p</italic> inhibitor or NC was conducted using a miRNA First Strand cDNA Synthesis kit that adopted A-tailing (B532461, Sangon Biotech). qPCR was performed using a miRNA qPCR kit (B532461, Sangon Biotech). Relative <italic>MIR539-5p</italic> level was normalized to U6 as the internal control. Primers were as follows: <italic>MIR539-5p</italic> forward, <italic>5′-<named-content content-type="sequence">CGCTGCATGGAGAAATTATCCT</named-content>-3′; MIR539-5p</italic> reverse, <italic>5′-<named-content content-type="sequence">CAGTGCAGGGTCCGAGGT</named-content>-3′</italic>; U6 forward, <italic>5′-<named-content content-type="sequence">GCTCGCTTCGGCAGCACATATAC</named-content>-3′</italic>, and U6 reverse <italic>5′-<named-content content-type="sequence">CGAATTTGCGTGTCATCCTTGCG</named-content>-3′</italic>. Thermocycling conditions were 95°C for 30 s, 40 cycles of 95°C for 5 s, and 60°C for 30 s. Relative mRNA levels were calculated using the 2<sup>-ΔΔCt</sup> method.</p></sec><sec id="s4-6"><title>CCK-8 analysis</title><p>Cells were seeded into 96-well plates at a density of 5000 cells per well. After 0, 24, 48, and 72 hr, CCK-8 (Cofitt Life Science Biotechnology) solution was added to each well, and cells were incubated for 3 hr. Optical density was measured at 450 nm using a microplate spectrophotometer (Bio-Rad). Experiments were performed in triplicate.</p></sec><sec id="s4-7"><title>Colony formation assay</title><p>SKBR3 and MDA-MB-231 cells were trypsinized and plated on 6-well plates at a density of 1000 cells per well. When visible colonies were formed, the cells were fixed with methyl alcohol and stained with crystal violet. The plates were photographed, and the number of colonies was counted using ImageJ software.</p></sec><sec id="s4-8"><title>Cell invasion and migration assay</title><p>For cell invasion, 20,000 cells in 0.2 mL serum-free culture medium were placed in the upper chamber of a Transwell chamber that had been precoated with Matrigel matrix. The lower chamber was filled with 1 mL culture medium containing 10% fetal bovine serum as the chemoattractant. After culturing at 37°C for 24 hr, cells that had migrated to the lower surface through the membrane were fixed with 4% paraformaldehyde for 10 min. Fixed cells were stained with crystal violet.</p><p>Detection of cell migration was similar to cell invasion, except the upper chamber of the Transwell chamber was not precoated with Matrigel.</p></sec><sec id="s4-9"><title>Immunohistochemistry</title><p>Surgically resected tissues were fixed in 4% formaldehyde, embedded in paraffin, and sectioned into 6-μm-thick slices. Sections were deparaffinized with xylene, rehydrated in a series of graded ethanols, and rinsed in Tris-buffered saline. Sections were incubated with a primary antibody anti-RGS10 (1:50; Abcam, Cambridge, MA; ab154172), anti-lipocalin-2 (LCN2) (1:500, ABclonal, #A2092), anti-E-cadherin (1:500, Proteintech, #20874-1-AP), anti-vimentin (1:200, HUABIO, #EM0401), anti-snail (1:100, ABclonal, # A5243), at 4°C overnight, incubated with a secondary antibody (Zhong Shan Jin Qiao Biotechnology Co, Beijing, China) at room temperature for approximately 45 min, and protein was visualized with a diaminobenzidine staining kit (Zhong Shan Jin Qiao Biotechnology Co).</p></sec><sec id="s4-10"><title>Immunofluorescence staining</title><p>After transfection with the <italic>MIR539-5p</italic> mimic or <italic>MIR539-5p</italic> inhibitor for 24 hr, SKBR3, and MDA-MB-231 cells were smeared on glass slides, cultured for 36 hr, and fixed with 4% paraformaldehyde for 20 min. Cells were washed three times with phosphate-buffered saline (PBS) and blocked with 5% bovine serum albumin in PBS (pH 7.4) at room temperature for 1 hr. Cells were incubated with anti-E-cadherin (1:100, Proteintech, #20874-1-AP), anti-vimentin (1:100, HUABIO, #EM0401), or anti-snail (1:100, ABclonal, #A5243) antibody at 4°C overnight. Cells were washed three times with PBS and incubated with Alexa Fluor 594 goat anti-mouse IgG H&amp;L or Alexa Fluor 488 goat anti-rabbit IgG H&amp;L (Proteintech, 1:400 dilution) at room temperature for 1 hr in the dark, washed three times, and incubated with 4′,6-diamidino-2-phenylindole (Solarbio, #C0065) for 10 min. After staining, cells were sealed with mounting media. Pictures were taken under a fluorescence microscope (Nikon, Japan).</p></sec><sec id="s4-11"><title>Western blotting</title><p>Cells were harvested by trypsinization and lysed in radioimmunoprecipitation assay lysis buffer. The cell lysate was centrifuged to a pellet (insoluble material). Proteins in the supernatant (30 µg of protein/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. After blocking with 5% w/v nonfat dry milk for 1 hr, membranes were incubated with anti-RGS10 (1:250; Abcam; ab154172), anti-GAPDH (1:1000, CST, 5174S), anti-lipocalin-2 (LCN2) (1:1000, ABclonal, #A2092), anti-E-cadherin (1:1000, Proteintech, #20874-1-AP), anti-vimentin (1:1000, HUABIO, #EM0401), anti-snail (1:1000, ABclonal, #A5243), or anti-β-tubulin (loading control) (1:5000, ABclonal, AC008) antibody at 4°C overnight. Membranes were incubated with a secondary antibody (Zhong Shan Jin Qiao Biotechnology Co) at 37°C for 1 hr. Bands were visualized using an enhanced chemiluminescent reagent. The relative protein levels of RGS10, LCN2, E-cadherin, vimentin, and snail were determined by densitometric analysis using Image Lab 6.0.1 software.</p></sec><sec id="s4-12"><title>Dual-luciferase reporter assay</title><p>The StarBase database was used to predict potential binding sites between <italic>RGS10</italic> mRNA and <italic>hsa-MIR539-5p</italic>. Sequences containing the 3'-untranslated region fragments of <italic>RGS10</italic> and the mutated binding site of <italic>hsa-MIR539-5p</italic> or wild type were designed and constructed by GeneChem Biotechnology (Shanghai, China). The <italic>MIR539-5p</italic> mimic or NC was cotransfected with the wild-type or mutant plasmid using Lipofectamine 3000 (Invitrogen). Luciferase intensity was recorded 48 hr after transfection using the dual-luciferase reporter assay system (Promega, Madison, WI).</p></sec><sec id="s4-13"><title>Molecular interaction networks</title><p>The Search Tool for the Retrieval of Interacting <italic>Genes</italic>/Proteins database (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>) was used to identify proteins that interact with RGS10 and conduct a protein–protein network interaction analysis (<xref ref-type="bibr" rid="bib41">Szklarczyk et al., 2015</xref>). Subsequently, the Database for Annotation, Visualization, and Integrated Discovery (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov">https://david.ncifcrf.gov</ext-link>) was used to perform GO and KEGG pathway-enrichment analysis.</p></sec><sec id="s4-14"><title>In vivo animal experiments</title><p>Nine BALB/C female nude mice (6 weeks old; 19–22 g) (Beijing Huafukang Biotechnology Company) were randomly assigned into three groups (n = 5 each). Mice were maintained in a specific-pathogen-free environment at 28°C and 50% humidity. The animal experiments were manipulated by the Regulations for the Administration of Affairs Concerning Experimental Animals and were approved by the Experimental Animal Ethics Committee of the Shengjing Hospital of China Medical University (Permit Number: 2024PS156K). A total of 1 × 10<sup>7</sup> SKBR3 cells transfected with shRNA-<italic>RGS10</italic> or shRNA-<italic>NC</italic> were injected subcutaneously to induce tumors. Tumor volume was measured every 3 days and calculated as V = 1/2 (width<sup>2</sup> × length). After subcutaneous injection of tumor cells for 30 days, mice were humanely euthanized and tumors were dissected and analyzed.</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Statistical analyses were conducted using SPSS 25.0 software. In vitro experiments were performed in triplicate. Associations between the <italic>RGS10</italic> gene and protein expression and clinicopathological characteristics were evaluated with the chi-square test or independent-samples <italic>t</italic>-test as appropriate. Survival curves were generated using the Kaplan–Meier method. Univariate and multivariate Cox regression analyses were used to identify prognostic predictors related to DFS and OS. Hazard ratios and corresponding 95% confidence intervals were calculated. All p-values were two-sided, with p&lt;0.05 considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Funding acquisition, Writing – original draft, Project administration, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study was approved by the Institutional Ethics Committee of Shengjing Hospital of China Medical University and complied with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the National Medical Products Administration of China. Informed consent was obtained from all the participants.</p></fn><fn fn-type="other"><p>The animal experiments were manipulated by the Regulations for the Administration of Affairs Concerning Experimental Animals and were approved by the Experimental Animal Ethics Committee of the Shengjing Hospital of China Medical University.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-97327-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in Dryad under the accession link: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.7h44j102r">https://doi.org/10.5061/dryad.7h44j102r</ext-link>. The data title is the transcriptomes in RGS10-depleted SKBR3 cells. All data generated or analyzed during the study are included in the manuscript and figures. Source data files have been provided for Figures 1-6. Raw gel/blot data for Figure 2, Figure 3, Figure 4, and Figure 5 were uploaded as source data files corresponding to the figures.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Qui</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Bu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>The transcriptomes in RGS10-depleted SKBR3 cells</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.7h44j102r</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnan</surname><given-names>M</given-names></name><name><surname>Morton</surname><given-names>G</given-names></name><name><surname>Hadi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Analysis of rpoS and bolA gene expression under various stress-induced environments in planktonic and biofilm phase using 2−ΔΔCT method</article-title><source>Molecular and Cellular Biochemistry</source><volume>357</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1007/s11010-011-0898-y</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almutairi</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Rada</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regulator of G protein signaling 10: Structure, expression and functions in cellular physiology and diseases</article-title><source>Cellular Signalling</source><volume>75</volume><elocation-id>109765</elocation-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109765</pub-id><pub-id pub-id-type="pmid">32882407</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alqinyah</surname><given-names>M</given-names></name><name><surname>Almutairi</surname><given-names>F</given-names></name><name><surname>Wendimu</surname><given-names>MY</given-names></name><name><surname>Hooks</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein-Independent Mechanism</article-title><source>Molecular Pharmacology</source><volume>94</volume><fpage>1103</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1124/mol.118.111674</pub-id><pub-id pub-id-type="pmid">30049816</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>MK</given-names></name><name><surname>Alshamrani</surname><given-names>AA</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Fambrough</surname><given-names>JM</given-names></name><name><surname>Tran</surname><given-names>SK</given-names></name><name><surname>Patel</surname><given-names>MB</given-names></name><name><surname>Hoseinzadeh</surname><given-names>P</given-names></name><name><surname>Beedle</surname><given-names>AM</given-names></name><name><surname>Murph</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells</article-title><source>Cancer Letters</source><volume>369</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.08.012</pub-id><pub-id pub-id-type="pmid">26319900</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="web"><person-group person-group-type="author"><collab>American Cancer Society</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Survival Rates for Breast Cancer</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html">https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html</ext-link><date-in-citation iso-8601-date="2024-01-17">January 17, 2024</date-in-citation></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchini</surname><given-names>G</given-names></name><name><surname>Balko</surname><given-names>JM</given-names></name><name><surname>Mayer</surname><given-names>IA</given-names></name><name><surname>Sanders</surname><given-names>ME</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease</article-title><source>Nature Reviews. Clinical Oncology</source><volume>13</volume><fpage>674</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.66</pub-id><pub-id pub-id-type="pmid">27184417</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacan</surname><given-names>E</given-names></name><name><surname>Ali</surname><given-names>MW</given-names></name><name><surname>Boyd</surname><given-names>NH</given-names></name><name><surname>Hooks</surname><given-names>SB</given-names></name><name><surname>Greer</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e87455</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0087455</pub-id><pub-id pub-id-type="pmid">24475290</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MiR-539 inhibits the malignant behavior of breast cancer cells by targeting SP1</article-title><source>Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire</source><volume>98</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1139/bcb-2019-0111</pub-id><pub-id pub-id-type="pmid">31742423</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldiran</surname><given-names>FY</given-names></name><name><surname>Cacan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma</article-title><source>Pathology, Research and Practice</source><volume>236</volume><elocation-id>154007</elocation-id><pub-id pub-id-type="doi">10.1016/j.prp.2022.154007</pub-id><pub-id pub-id-type="pmid">35810565</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhury</surname><given-names>S</given-names></name><name><surname>O’Connor</surname><given-names>C</given-names></name><name><surname>Cañete</surname><given-names>A</given-names></name><name><surname>Bittencourt-Silvestre</surname><given-names>J</given-names></name><name><surname>Sarrou</surname><given-names>E</given-names></name><name><surname>Prendergast</surname><given-names>Á</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Johnston</surname><given-names>P</given-names></name><name><surname>Wells</surname><given-names>CA</given-names></name><name><surname>Gibson</surname><given-names>B</given-names></name><name><surname>Keeshan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>5280</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07584-1</pub-id><pub-id pub-id-type="pmid">30538250</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>M</given-names></name><name><surname>Thürlimann</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name><collab>Panel Members</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>1533</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv221</pub-id><pub-id pub-id-type="pmid">25939896</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>P</given-names></name><name><surname>Hooks</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of RGS10 in the ovarian cancer microenvironment</article-title><source>The FASEB Journal</source><volume>34</volume><elocation-id>05803</elocation-id><pub-id pub-id-type="doi">10.1096/fasebj.2020.34.s1.05803</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>AP</given-names></name><name><surname>Vasaikar</surname><given-names>SV</given-names></name><name><surname>Tomczak</surname><given-names>K</given-names></name><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>den Hollander</surname><given-names>P</given-names></name><name><surname>Arslan</surname><given-names>E</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Soundararajan</surname><given-names>R</given-names></name><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2102050118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2102050118</pub-id><pub-id pub-id-type="pmid">33941680</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Górecki</surname><given-names>I</given-names></name><name><surname>Rak</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of microRNAs in epithelial to mesenchymal transition and cancers; focusing on mir-200 family</article-title><source>Cancer Treatment and Research Communications</source><volume>28</volume><elocation-id>100385</elocation-id><pub-id pub-id-type="doi">10.1016/j.ctarc.2021.100385</pub-id><pub-id pub-id-type="pmid">34023767</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradishar</surname><given-names>WJ</given-names></name><name><surname>Moran</surname><given-names>MS</given-names></name><name><surname>Abraham</surname><given-names>J</given-names></name><name><surname>Aft</surname><given-names>R</given-names></name><name><surname>Agnese</surname><given-names>D</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Blair</surname><given-names>SL</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Elias</surname><given-names>AD</given-names></name><name><surname>Giordano</surname><given-names>SH</given-names></name><name><surname>Goetz</surname><given-names>MP</given-names></name><name><surname>Goldstein</surname><given-names>LJ</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Isakoff</surname><given-names>SJ</given-names></name><name><surname>Jankowitz</surname><given-names>RC</given-names></name><name><surname>Javid</surname><given-names>SH</given-names></name><name><surname>Krishnamurthy</surname><given-names>J</given-names></name><name><surname>Leitch</surname><given-names>M</given-names></name><name><surname>Lyons</surname><given-names>J</given-names></name><name><surname>Matro</surname><given-names>J</given-names></name><name><surname>Mayer</surname><given-names>IA</given-names></name><name><surname>Mortimer</surname><given-names>J</given-names></name><name><surname>O’Regan</surname><given-names>RM</given-names></name><name><surname>Patel</surname><given-names>SA</given-names></name><name><surname>Pierce</surname><given-names>LJ</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Sitapati</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>KL</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Soliman</surname><given-names>H</given-names></name><name><surname>Stringer-Reasor</surname><given-names>EM</given-names></name><name><surname>Telli</surname><given-names>ML</given-names></name><name><surname>Ward</surname><given-names>JH</given-names></name><name><surname>Wisinski</surname><given-names>KB</given-names></name><name><surname>Young</surname><given-names>JS</given-names></name><name><surname>Burns</surname><given-names>JL</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NCCN Guidelines Insights: Breast Cancer, Version 4.2021</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>19</volume><fpage>484</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2021.0023</pub-id><pub-id pub-id-type="pmid">34794122</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>2073</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-20431-z</pub-id><pub-id pub-id-type="pmid">29391441</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Győrffy</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer</article-title><source>Computational and Structural Biotechnology Journal</source><volume>19</volume><fpage>4101</fpage><lpage>4109</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.07.014</pub-id><pub-id pub-id-type="pmid">34527184</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooks</surname><given-names>SB</given-names></name><name><surname>Callihan</surname><given-names>P</given-names></name><name><surname>Altman</surname><given-names>MK</given-names></name><name><surname>Hurst</surname><given-names>JH</given-names></name><name><surname>Ali</surname><given-names>MW</given-names></name><name><surname>Murph</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells</article-title><source>Molecular Cancer</source><volume>9</volume><elocation-id>289</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-9-289</pub-id><pub-id pub-id-type="pmid">21044322</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooks</surname><given-names>SB</given-names></name><name><surname>Murph</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer</article-title><source>Future Medicinal Chemistry</source><volume>7</volume><fpage>1483</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.4155/fmc.15.81</pub-id><pub-id pub-id-type="pmid">26293348</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Gou</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>O</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer</article-title><source>Genomics</source><volume>113</volume><fpage>2134</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2021.04.012</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis</article-title><source>Journal of Hematology &amp; Oncology</source><volume>15</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-022-01347-8</pub-id><pub-id pub-id-type="pmid">36076302</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>TW</given-names></name><name><surname>Fields</surname><given-names>TA</given-names></name><name><surname>Casey</surname><given-names>PJ</given-names></name><name><surname>Peralta</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>RGS10 is a selective activator of Gαi GTPase activity</article-title><source>Nature</source><volume>383</volume><fpage>175</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/383175a0</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epithelial-Mesenchymal Transition and Metabolic Switching in Cancer: Lessons From Somatic Cell Reprogramming</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><elocation-id>760</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.00760</pub-id><pub-id pub-id-type="pmid">32850862</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>15</volume><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nrm3758</pub-id><pub-id pub-id-type="pmid">24556840</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AV</given-names></name><name><surname>Oesterreich</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>107</volume><elocation-id>djv073</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djv073</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CJ</given-names></name><name><surname>Chu</surname><given-names>PY</given-names></name><name><surname>Yiang</surname><given-names>GT</given-names></name><name><surname>Wu</surname><given-names>MY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis</article-title><source>Biomolecules</source><volume>9</volume><elocation-id>476</elocation-id><pub-id pub-id-type="doi">10.3390/biom9090476</pub-id><pub-id pub-id-type="pmid">31514467</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>RGS proteins and their roles in cancer: friend or foe?</article-title><source>Cancer Cell International</source><volume>23</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1186/s12935-023-02932-8</pub-id><pub-id pub-id-type="pmid">37118788</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Pinchback</surname><given-names>R</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id><pub-id pub-id-type="pmid">21546393</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Gu</surname><given-names>LN</given-names></name><name><surname>Shan</surname><given-names>BE</given-names></name><name><surname>Geng</surname><given-names>CZ</given-names></name><name><surname>Sang</surname><given-names>MX</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Biomarkers for EMT and MET in breast cancer: An update</article-title><source>Oncology Letters</source><volume>12</volume><fpage>4869</fpage><lpage>4876</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.5369</pub-id><pub-id pub-id-type="pmid">28105194</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlin</surname><given-names>JL</given-names></name><name><surname>Barberi-Heyob</surname><given-names>M</given-names></name><name><surname>Bachmann</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines</article-title><source>Annals of Oncology</source><volume>13</volume><fpage>1743</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdf263</pub-id><pub-id pub-id-type="pmid">12419746</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miglietta</surname><given-names>F</given-names></name><name><surname>Bottosso</surname><given-names>M</given-names></name><name><surname>Griguolo</surname><given-names>G</given-names></name><name><surname>Dieci</surname><given-names>MV</given-names></name><name><surname>Guarneri</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival</article-title><source>ESMO Open</source><volume>7</volume><elocation-id>100409</elocation-id><pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100409</pub-id><pub-id pub-id-type="pmid">35227965</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montel</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>TY</given-names></name><name><surname>Mose</surname><given-names>E</given-names></name><name><surname>Pestonjamasp</surname><given-names>K</given-names></name><name><surname>Tarin</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model</article-title><source>The American Journal of Pathology</source><volume>166</volume><fpage>1565</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)62372-3</pub-id><pub-id pub-id-type="pmid">15855655</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Valencia</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>L</given-names></name><name><surname>Martí-Nin</surname><given-names>T</given-names></name><name><surname>Ozerdem</surname><given-names>U</given-names></name><name><surname>David</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression</article-title><source>Oncogene</source><volume>41</volume><fpage>4361</fpage><lpage>4370</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02433-4</pub-id><pub-id pub-id-type="pmid">35953598</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Murph</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?</article-title><source>Frontiers in Oncology</source><volume>4</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00071</pub-id><pub-id pub-id-type="pmid">24782983</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>R</given-names></name><name><surname>Dhruba</surname><given-names>SR</given-names></name><name><surname>Matlock</surname><given-names>K</given-names></name><name><surname>De-Niz</surname><given-names>C</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Pal</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluating the consistency of large-scale pharmacogenomic studies</article-title><source>Briefings in Bioinformatics</source><volume>20</volume><fpage>1734</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1093/bib/bby046</pub-id><pub-id pub-id-type="pmid">31846027</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago-Sánchez</surname><given-names>GS</given-names></name><name><surname>Pita-Grisanti</surname><given-names>V</given-names></name><name><surname>Quiñones-Díaz</surname><given-names>B</given-names></name><name><surname>Gumpper</surname><given-names>K</given-names></name><name><surname>Cruz-Monserrate</surname><given-names>Z</given-names></name><name><surname>Vivas-Mejía</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>4365</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21124365</pub-id><pub-id pub-id-type="pmid">32575507</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Chakrabarti</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells</article-title><source>Journal of Clinical Medicine</source><volume>8</volume><elocation-id>642</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8050642</pub-id><pub-id pub-id-type="pmid">31075939</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>New insights into the tumor metastatic process revealed by gene expression profiling</article-title><source>The American Journal of Pathology</source><volume>166</volume><fpage>1291</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)62348-6</pub-id><pub-id pub-id-type="pmid">15855631</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez-Carmona</surname><given-names>M</given-names></name><name><surname>Lesage</surname><given-names>J</given-names></name><name><surname>Cataldo</surname><given-names>D</given-names></name><name><surname>Gilles</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EMT and inflammation: inseparable actors of cancer progression</article-title><source>Molecular Oncology</source><volume>11</volume><fpage>805</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12095</pub-id><pub-id pub-id-type="pmid">28599100</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA</source><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Forslund</surname><given-names>K</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>A</given-names></name><name><surname>Tsafou</surname><given-names>KP</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D447</fpage><lpage>D452</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id><pub-id pub-id-type="pmid">25352553</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H-T</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4</article-title><source>Cell Death &amp; Disease</source><volume>13</volume><elocation-id>656</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-05093-0</pub-id><pub-id pub-id-type="pmid">35902557</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients</article-title><source>Cell Research</source><volume>25</volume><elocation-id>1376</elocation-id><pub-id pub-id-type="doi">10.1038/cr.2015.141</pub-id><pub-id pub-id-type="pmid">26620315</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><name><surname>Hammond</surname><given-names>MEH</given-names></name><name><surname>Hicks</surname><given-names>DG</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Bartlett</surname><given-names>JMS</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Fitzgibbons</surname><given-names>P</given-names></name><name><surname>Hanna</surname><given-names>W</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Mangu</surname><given-names>PB</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Spears</surname><given-names>PA</given-names></name><name><surname>Vance</surname><given-names>GH</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><collab>American Society of Clinical Oncology</collab><collab>College of American Pathologists</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update</article-title><source>Journal of Clinical Oncology</source><volume>31</volume><fpage>3997</fpage><lpage>4013</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.9984</pub-id><pub-id pub-id-type="pmid">24101045</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Bielenberg</surname><given-names>DR</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Doiron</surname><given-names>R</given-names></name><name><surname>Clifton</surname><given-names>MC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>Moses</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Lipocalin 2 promotes breast cancer progression</article-title><source>PNAS</source><volume>106</volume><fpage>3913</fpage><lpage>3918</lpage><pub-id pub-id-type="doi">10.1073/pnas.0810617106</pub-id><pub-id pub-id-type="pmid">19237579</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells</article-title><source>Brazilian Journal of Medical and Biological Research = Revista Brasileira de Pesquisas Medicas e Biologicas</source><volume>46</volume><fpage>546</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1590/1414-431X20131662</pub-id><pub-id pub-id-type="pmid">23780424</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Corsa</surname><given-names>CA</given-names></name><name><surname>Ponik</surname><given-names>SM</given-names></name><name><surname>Prior</surname><given-names>JL</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name><name><surname>Keely</surname><given-names>PJ</given-names></name><name><surname>Longmore</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/ncb2743</pub-id><pub-id pub-id-type="pmid">23644467</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Ang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MicroRNAs regulate the epithelial–mesenchymal transition and influence breast cancer invasion and metastasis</article-title><source>Tumor Biology</source><volume>39</volume><elocation-id>101042831769168</elocation-id><pub-id pub-id-type="doi">10.1177/1010428317691682</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97327.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Wuhan University</institution><country>China</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> article first demonstrated that RGS10 was identified as a biomarker to evaluate the prognosis of breast cancer. To prevent the loss of RGS10, it theoretically provides a new strategy for the treatment of breast cancer. The evidence supporting the claims of the authors is <bold>solid</bold>, although inclusion of a larger number of patient samples and an animal model would have strengthened the study. The work will be of interest to clinicians working on breast cancer.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97327.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The paper has shown the expression of RGS10 is related to the molecular subtype, distant metastasis, and survival status of breast cancer. The study utilizes bioinformatic analyses, human tissue samples, and in vitro and in vivo experiments which strengthen the data. RGS10 was validated to inhibit EMT through a novel mechanism dependent on LCN2 and miR-539-5p, thereby reducing cancer cell proliferation, colony formation, invasion, and migration. The study elaborated on the function of RGS10 in influencing the prognosis and biological behavior which could be considered as a potential drug target in breast cancer.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97327.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Liu et al., by focusing on the regulation of G protein-signaling 10 (RGS10), reported that RGS10 expression was significantly lower in patients with breast cancer, compared with normal adjacent tissue. Genetic inhibition of RGS10 caused epithelial-mesenchymal transition, and enhanced cell proliferation, migration, and invasion, respectively. These results suggest an inhibitory role of RGS10 in tumor metastasis. Furthermore, bioinformatic analyses determined signaling cascades for RGS10-mediated breast cancer distant metastasis. More importantly, both in vitro and in vivo studies evidenced that alteration of RGS10 expression by modulating its upstream regulator miR-539-5p affects breast cancer metastasis. Altogether, these findings provide insight into the pathogenesis of breast tumors and hence identify potential therapeutic targets in breast cancer.</p><p>The conclusions of this study are mostly well supported by data.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97327.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Distant metastasis is the major cause of death in patients with breast cancer. In this manuscript, Liu et al. show that RGS10 deficiency elicits distant metastasis via epithelial-mesenchymal transition in breast cancer. As a prognostic indicator of breast cancer, RGS10 regulates the progress of breast cancer and affects tumor phenotypes such as epithelial-mesenchymal transformation, invasion, and migration. The conclusions of this paper are mostly well supported by data.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97327.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yang</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yi</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Peng</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Tie</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Yang</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Bu</surname><given-names>Jiawen</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical Universit</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yueting</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Ming</given-names></name><role specific-use="author">Author</role><aff><institution>Shengjing Hospital of China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Tong</given-names></name><role specific-use="author">Author</role><aff><institution>Panjin Central Hospital</institution><addr-line><named-content content-type="city">Panjin</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Xi</given-names></name><role specific-use="author">Author</role><aff><institution>China Medical University</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This study presents a valuable finding on the mechanism to promote distant metastasis in breast cancer. The evidence supporting the claims of the authors is convincing. The work will be of interest to medical biologists working on breast cancer.</p><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Strengths</p><p>The paper has shown the expression of RGS10 is related to the molecular subtype, distant metastasis, and survival status of breast cancer. The study utilizes bioinformatic analyses, human tissue samples, and in vitro and in vivo experiments which strengthen the data. RGS10 was validated to inhibit EMT through a novel mechanism dependent on LCN2 and miR-539-5p, thereby reducing cancer cell proliferation, colony formation, invasion, and migration. The study elaborated the function of RGS10 in influencing the prognosis and biological behavior which could be considered as a potential drug target in breast cancer.</p><p>Weakness</p><p>The mechanism by which the miR-539-5p/RGS10/LCN2 axis may be related to the prognosis of cancer patients still needs to be elucidated. In addition, the sample size used is relatively limited. Especially, if further exploration of the related pathways and mechanisms of LCN2 can be carried out by using organoid models, as well as the potential of RGS10 as a biomarker for further clinical translation to verify its therapeutic target effect, which will make the data more convincing.</p></disp-quote><p>Answer: Thank you for your comments and suggestions. In future research, we will utilize large clinical cohorts and organoid models to further explore relevant research mechanisms.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Liu et al., by focusing on the regulation of G protein-signaling 10 (RGS10), reported that RGS10 expression was significantly lower in patients with breast cancer, compared with normal adjacent tissue. Genetic inhibition of RGS10 caused epithelial-mesenchymal transition, and enhanced cell proliferation, migration, and invasion, respectively. These results suggest an inhibitory role of RGS10 in tumor metastasis. Furthermore, bioinformatic analyses determined signaling cascades for RGS10-mediated breast cancer distant metastasis. More importantly, both in vitro and in vivo studies evidenced that alteration of RGS10 expression by modulating its upstream regulator miR-539-5p affects breast cancer metastasis. Altogether, these findings provide insight into the pathogenesis of breast tumors and hence identify potential therapeutic targets in breast cancer.</p><p>The conclusions of this study are mostly well supported by data. However, there is a weakness in the study that needs to be clarified.</p><p>In Figure 2A, although some references supported that SKBR3 and MCF-7 possess poorly aggressive and less invasive abilities, examining only RGS10 expression in those cells, it could not be concluded that 'RGS10 acts as a tumor suppressor in breast cancer'. It would be better to introduce a horizontal comparison of the invasive ability of these 3 types of cells using an invasion assay.</p></disp-quote><p>Answer: Thank you for your comments and suggestions. MDA-MB-231, SKBR3, and MCF-7 originate from triple-negative breast cancer (high invasiveness), Her-2 receptor overexpression (relatively weak invasiveness), and luminal type breast cancer (relatively weak invasiveness) separately. Previous studies have demonstrated the invasive ability of these 3 types of cells. (PMID: <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34390568">34390568</ext-link>)</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Distant metastasis is the major cause of death in patients with breast cancer. In this manuscript, Liu et al. show that RGS10 deficiency elicits distant metastasis via epithelial-mesenchymal transition in breast cancer. As a prognostic indicator of breast cancer, RGS10 regulates the progress of breast cancer and affects tumor phenotypes such as epithelial-mesenchymal transformation, invasion, and migration. The conclusions of this paper are mostly well supported by data, but some analyses need to be clarified.</p><p>(1) Because diverse biomarkers have been identified for EMT, it is recommended to declare the advantages of using RGS10 as an EMT marker.</p></disp-quote><p>Answer: Thank you for your comments. The dysregulation of RGS protein expression has been observed to be associated with various types of cancer. (PMID: 26293348). Previous studies have shown that RGS10 knocking down can lead to chemotherapy resistance of ovarian cancer cells to paclitaxel, cisplatin, and vincristine. In colorectal tumors, the transcription of RGS10 is regulated by DNA methylation and histone deacetylation. As a key regulatory factor in the G protein signaling pathway, RGS 10 is involved in tumor development including survival, polarization, adhesion, chemotaxis, and differentiation, these hints suggest RGS10 might be a marker for EMT in breast cancer.</p><disp-quote content-type="editor-comment"><p>(2) The authors utilized databases to study the upstream regulatory mechanisms of RSG10. It is recommended to clarify why the authors focused on miRNAs rather than other epigenetic modifications.</p></disp-quote><p>Answer: Thank you for your comments. miRNAs are short-chain non-coding RNA molecules that bind to the target mRNA's 3 'untranslated region (3'UTR) to cause mRNA degradation or translation inhibition, thus regulating gene expression in cells. These small molecules play a crucial role in regulating the expression of cancer-related genes and can act as tumor promoters or tumor suppressors. To further improve the molecular mechanism of malignant biological behavior of breast cancer cells with RGS10, we verified that miR-539-5p might be the upstream regulation target of RGS10 through bioinformatics prediction and in-vitro experiments.</p><disp-quote content-type="editor-comment"><p>(3) The role of miR-539-5p in breast cancer has been described in previous studies. Hence, it is recommended to provide detailed elaboration on how miR-539-5p regulates the expression of RSG10.</p></disp-quote><p>Answer: Thank you for your comments. To verify the effect of miRNA-539-5p regulating the expression of RSG10, we transfected miR-539-5p mimic, miR-539-5p mimic NC, miR-539-5p inhibitor, miR-539-5p inhibitor NC in SKBR3 cells and MDA-MB-231 cells respectively, and verified the expression of RGS10 through RT-qPCR and Western blot experiments. The results showed that compared with the transfected miR-539-5p mimic NC or wild-type SKBR3 cells, RGS10 m RNA and protein levels were significantly reduced. On the contrary, after MDA-MB-231 cells were transfected with miR-539-5p inhibitor to inhibit the expression of miR-539-5p, RGS10 mRNA and protein levels in MDA-MB-231 cells were significantly increased (Fig. 3.4A-C, Fig. 3.5A-C). This indicates that miR-539-5p can target and regulate RGS10.</p><disp-quote content-type="editor-comment"><p>(4) To enhance the clarity and interpretability of the Western blot results, it would be advisable to mark the specific kilodalton (kDa) values of the proteins.</p></disp-quote><p>Answer: Thank you for your comments and suggestions. We have corrected to mark the specific kilodalton (kDa) values of the proteins in WB.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The function of RGS10 in breast cancer was identified in the paper. However, some major issues in this paper need to be specified:</p><p>(1) From reading the introduction section and its references, RGS proteins participate in multiple essential cellular processes and may be tumor initiators or suppressors (Li et al., 2023). This article focuses on the significance of RGS10 in breast cancer, it is recommended to show how the function of RGS10 exhibits therapeutic significance in other types of cancer.</p></disp-quote><p>Answer: Thanks for your comments and suggestions on our findings. The dysregulation of RGS protein expression has been observed to be associated with various types of cancer. Especially in ovarian cancer cells. (PMID: 26293348). It has been found that the RGS10 expression is lower than that of normal ovarian cells. (PMID: 21044322). In addition, it has been found that knocking down RGS10 can enhance the vitality of ovarian cancer cells and promote chemoresistance by activating the Rheb GTP/mTOR signaling pathway. (PMID: 26319900). A study suggests that RGS10 mediates inflammation signaling regulation in SKOV-3 ovarian cancer cells with high expression of TNF and COX-2 after RGS10 knockdown. In colorectal tumors, RGS10 transcription is regulated by DNA methylation and histone deacetylation. (PMID: 35810565). RGS10 expression also are associated with poor prognosis in laryngeal cancer, hepatocellular carcinoma, and pediatric acute myeloid leukemia. (PMID: 32776811, PMID: 26516143, PMID: 30538250)</p><disp-quote content-type="editor-comment"><p>(2) The authors characterize RGS10 protein expression in the breast cancer cell lines MDA-MB-231, MCF7, and SKBR3 in vitro Figure 2A. However, more information would strengthen the data - e.g. information on the expression of RGS10 protein and the survival in public databases, as well as the correlation between RGS10 and Her-2 expression.</p></disp-quote><p>Answer: Thanks for your comments. we have checked the correlation of RGS10 expression and survival rate of Her-2 positive breast cancer patients in a public database. Although there is no significant difference in the “p” value, however, RGS10 high-expression patients have a favorable prognosis tendency than RGS10 low-expression patients after the 100th month.</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97327-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) Regarding the current situation of clinical trials in the RGS family, the potential to develop RGS 10 for clinic translation is a driving factor for EMT.</p></disp-quote><p>Answer: Thank you for your comments. The RGS (G protein signal transduction regulator) gene family provides an important &quot;braking&quot; function for the cell receptor family of G-protein coupled receptors (GPCR). GPCR controls hundreds of important functions in systemic cells and is the largest class of drug targets, with over one-third of FDA approved drugs treating diseases by binding to GPCR and altering its activity. When GPCRs are activated by hormones or neurotransmitters, they initiate signaling cascades within host cells through signal-carrying proteins called G proteins. The function of the RGS protein is to inactivate the G protein, thereby shutting down this signaling cascade reaction, which limits G protein signal transduction and allows cells to reset and receive new incoming signals. If it were not for it, the signals triggered by GPCR would inappropriately remain on, and the signal transduction would experience dysfunction (PMID: 33007266). The potential to develop RGS10 as a driving factor of EMT is meaningful for clinic translation.</p><disp-quote content-type="editor-comment"><p>(4) In Figure 3A, the paper showed that differential gene expression revealed 70 genes were significantly upregulated in RGS10-depleted SKBR3 cells, The authors didn't show any data on the expression of other EMT-related proteins in pathway analysis.</p></disp-quote><p>Answer: Thank you for your comments. The enrichment analysis of RNA sequencing in RGS10-depleted SKBR3 cells suggests that high correlation factors that are associated with EMT, such as TAGLN, TNFSF10, NDUFA4L2, CCN5, PHGDH, ST3GAL5, ANG, and LCN2.</p><disp-quote content-type="editor-comment"><p>(5) In Figure 3B, the paper focuses on LCN2 in pathway analysis, however, the author did not elaborate on the significance of LCN2-related pathways in EMT.</p></disp-quote><p>Answer: Thank you for your comments. Some studies have the significance of LCN2-related pathways in EMT. It was confirmed that LCN2 upregulation triggered by PTEN insufficiency induces EMT to promote migration and invasion in MCF7 cells (PMID: 27466505). The activation of STAT3 contributes to an increase in LCN2 expression, which activates ERK pathway-dependent EMT, thus promoting lung metastasis in MDA-MB-231 cells in breast cancer (PMID: 33473115). The silencing of LCN2 reduced the ability of migration and invasion of SUM149 cells and the proportion of tumor stem cells, suggesting that LCN2 may mediate the invasion and metastasis of cancer cells by regulating the stemness of breast cancer cells. The biological effects of LCN2 small molecule inhibitors ZINC00640089 and ZINC00784494 targeting IBC cells have been confirmed. The siRNA-mediated silencing of LCN2 in IBC cells significantly reduces cell proliferation, viability, migration, and invasion. (PMID: 34445288).</p><disp-quote content-type="editor-comment"><p>(6) Minor: the author did not conduct a semi-quantitative analysis of the immunohistochemical results of RGS10.</p></disp-quote><p>Answer: Thank you for your suggestion. We would like to demonstrate the qualitative analysis of RGS10 immunohistochemistry. The semi-quantitative analysis is not required in the paper.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The role of RGS10 was well-characterized in this study, However, some minor points need to be modified.</p><p>(1) Page 15 line 296, description of cell proliferation was missing, please modify.</p></disp-quote><p>Answer: Thank you for your comments. We have corrected the description of cell proliferation on Page 15 highlighted in red.</p><disp-quote content-type="editor-comment"><p>(2) In Figure 2C, the title of the Y-axis was missing.</p></disp-quote><p>Answer: Thank you for your comments. We have corrected the description of the Y-axis title in Figure 2C.</p><disp-quote content-type="editor-comment"><p>(3) Describe the transfection reagent that was used in this study, and incorporated into the methods section.</p></disp-quote><p>Answer: Thank you for your comments. We have added the description of the transfection reagent to the methods section.</p><disp-quote content-type="editor-comment"><p>(4) The manuscript needs proofreading.</p></disp-quote><p>Answer: Thank you for your comments. We have proofread the manuscript.</p></body></sub-article></article>